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Abstract: IgE antibodies are well known for their role in mediating allergic reactions, their 12 
powerful effector functions activated through binding to Fc receptors FcRI and FcRII/CD23. 13 
Structural studies of IgE-Fc alone and when bound to these receptors surprisingly revealed not 14 
only an acutely bent Fc conformation, but also subtle allosteric communication between the two 15 
distant receptor-binding sites. The ability of IgE-Fc to undergo more extreme conformational 16 
changes emerged from structures of complexes with anti-IgE antibodies, including omalizumab, in 17 
clinical use for allergic disease; flexibility is clearly critical for IgE function, but may also be 18 
exploited by allosteric interference to inhibit IgE activity for therapeutic benefit. In contrast, the 19 
power of IgE may be harnessed to target cancer. Efforts to improve the effector functions of 20 
therapeutic antibodies for cancer have almost exclusively focussed on IgG1 and IgG4 isotypes, but 21 
IgE offers extremely high affinity for cognate FcRI receptors on immune effector cells known to 22 
infiltrate solid tumours. Furthermore, while tumour-resident inhibitory Fc receptors can modulate 23 
the effector functions of IgG antibodies, no inhibitory IgE Fc receptors are known to exist. The 24 
development of tumour antigen-specific IgE antibodies may therefore provide an improved 25 
immune functional profile and enhanced anti-cancer efficacy. We describe proof-of-concept studies 26 
of IgE immunotherapies against solid tumours, including a range of in vitro and in vivo evaluations 27 
of efficacy and mechanisms of action, as well as ex vivo and in vivo safety studies. The first 28 
anti-cancer IgE antibody, MOv18, the clinical translation of which we discuss herein, has now 29 
reached clinical testing, offering great potential to direct this novel therapeutic modality against 30 
many other tumour-specific antigens. This review highlights how our understanding of IgE 31 
structure and function underpins these exciting clinical developments.   32 
Keywords: Immunoglobulin E; FcεRI; CD23; allostery; cancer immunotherapy; AllergoOncology; 33 
IgE effector functions; monocytes; macrophages; ADCC. 34 
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, 35 
antibody-dependent cell-mediated phagocytosis; APC, antigen presenting cell; BAL, 36 
broncho-alveolar lavage; BAT, basophil activation test; CCA, colorectal cancer antigen; CDR, 37 
complementarity-determining region; CTCs, circulating tumour cells; CTL, cytotoxic T 38 
lymphocyte; DCs, dendritic cells; EGFR, epidermal growth factor receptor; EM, electron 39 
microscopy; FR, framework region; FRα, folate receptor alpha; FRET, fluorescence (Förster) 40 
resonance energy transfer; GMP, Good Manufacturing Practice; IHC, immunohistochemical / 41 
immunohistochemistry; i.p., intraperitoneal; i.v., intravenous; MCP-1, macrophage 42 
chemoattractant protein-1; MD, molecular dynamics; MMTV, mammary tumour virus; NIP, 43 
4-hydroxy-3-nitro-phenacetyl; NK, Natural Killer; PBMCs, peripheral blood mononuclear cells; 44 
PDX, patient-derived xenograft; PIPE, Polymerase Incomplete Primer Extension; PSA, prostate 45 
specific antigen; RBL, rat basophil leukaemia; SAXS, small-angle X-ray scattering; s.c., 46 
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subcutaneous; Th, T helper; TME, tumour microenvironment; TNFα, tumour necrosis factor; 47 
UCOE, Ubiquitous Chromatin Opening Elements; WAG, Wistar Albino Glaxo. 48 
 49 
1. Introduction 50 
Immunoglobulin E (IgE), named in 1968 [1-3], was the last of the five classes of human antibody to 51 
be discovered, and is commonly associated today with the various manifestations of allergic disease 52 
[4]. However, its role in mammalian evolution appears to be the provision of a mechanism for 53 
defence against parasites and animal venoms [5], and in this regard it required the acquisition of a 54 
powerful effector function. It is precisely this power, and the possibility of understanding and 55 
harnessing it, that makes IgE an attractive candidate for monoclonal antibody immunotherapy 56 
against clinically important targets. IgE differs from the various sub-classes of IgG that have hitherto 57 
been the common format for therapeutic antibodies in a number of key aspects, including its domain 58 
architecture, glycosylation, conformational dynamics and, as only recently appreciated, allosteric 59 
properties [6]. In this review we bring together our understanding of the structural and functional 60 
properties of IgE and show how this underpins the development of IgE as a therapeutic antibody 61 
format.     62 
 63 
IgE’s receptor-binding activities also present unique features. There are two principal receptors, 64 
FcεRI, structurally homologous to other members of the FcγR family, and FcεRII/CD23 which, 65 
unlike almost all other antibody receptors, is a member of the C-type (Ca2+-dependent) lectin-like 66 
superfamily [4]. FcεRI is expressed on tissue mast cells, blood basophils, airway epithelial and 67 
smooth muscle cells, intestinal epithelial cells, and various antigen-presenting cells (APCs), 68 
monocytes and macrophages [7-11]; the cross-linking of receptor-bound allergen-specific IgE on 69 
mast cells and basophils by allergen is the signal for cell degranulation, release of pre-formed 70 
mediators of inflammation and an immediate hypersensitivity response that can be powerful 71 
enough to cause anaphylactic shock and even death. Not only is it necessary to cross-link only very 72 
few IgE and FcεRI molecules in this way, compared with IgG and FcγR, but the affinity of IgE for 73 
FcεRI (Ka ≈ 1010 M-1) is at least two orders of magnitude higher than that of IgG for any of its 74 
receptors. Thus, most IgE is already cell bound, and all that is required is contact with perhaps a 75 
minute amount of allergen to trigger a rapid reaction. In contrast, IgG generally requires the 76 
formation of immune complexes consisting of many more antibody molecules, which can then, upon 77 
contact with an effector cell, cause FcγR clustering and cell activation [12]. With its uniquely high 78 
affinity for any antibody-receptor interaction, FcεRI is often referred to as the “high-affinity” 79 
receptor for IgE. 80 
 81 
FcRII, or CD23 as it will be called here, is also known as the “low-affinity” receptor for IgE. 82 
While the affinity of each of its lectin-like “heads” for IgE (Ka  106 M-1) is indeed much lower than 83 
that of FcRI, the fact that the molecule is trimeric can lead to a higher avidity if more than one head 84 
can engage IgE; this will be discussed in detail later. CD23 is expressed on B cells, T cells, various 85 
APCs, gut and airway epithelial cells and a range of other cell types [13-18]. On B cells, IgE binding 86 
to CD23, the latter behaving both as a membrane protein and also as a soluble protein released from 87 
the cell surface (in trimeric or monomeric form) by endogenous or exogenous proteases, can either 88 
up- or down-regulate IgE levels [13,19-21]. This interplay between IgE and both membrane and 89 
soluble CD23 has been proposed to constitute a mechanism for IgE homeostasis. CD23 also transfers 90 
IgE-allergen complexes across the airway and gut epithelia and thus promotes presentation of 91 
airborne and food allergens to the immune system [16-18,22]. 92 
 93 
There is a considerable body of structural data concerning the interactions between IgE-Fc and 94 
the receptors FcRI and CD23. There is also a good understanding, if based upon rather few 95 
examples, of how IgE Fabs recognise allergens; this understanding was recently enhanced by the 96 
discovery that allergen recognition may occur not only in a classical, complementarity-determining  97 
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Figure 1. Overall structure and glycosylation. (a) Schematic representation of IgG. (b) Schematic 99 
representation of IgE. (c) The IgG C2 domain contains complex carbohydrate covalently attached to 100 
Asn297 [24]. (d) The IgE C3 domain contains high-mannose carbohydrate covalently attached to 101 
Asn394 [25]. In panels (c) and (d), carbohydrate residues are labelled as follows: FUC, fucose; GAL, 102 
galactose; MAN, mannose; NAG, N-acetylglucosamine; SIA, sialic acid. 103 
region (CDR)-mediated manner, but also through V-region framework regions (FR) in a 104 
“superantigen-like” mode [23]. When we put these structural data together to build models of the 105 
whole IgE molecule it is clear that there are constraints upon the disposition of the Fab arms when 106 
the Fc is receptor bound, and similarly there may be restrictions upon the receptor-binding 107 
capability of the Fc region when IgE engages target antigens; unfortunately we lack high-resolution 108 
structural data on the complete IgE molecule. Appreciation of these constraints and the 109 
consequences of the flexibility and dynamics of the IgE molecule as a whole, are clearly important 110 
for engineering an IgE molecule for immunotherapy that combines the desired antigen-binding and 111 
receptor-mediated activities.  112 
  113 
2. The structure of IgE 114 
The overall architecture of the IgE molecule differs most significantly from that of IgG in respect of 115 
the “additional” heavy chain constant domain (Figures 1a and 1b) and absence of a hinge region in 116 
the -chain. The six domains comprising the IgE-Fc, a dimer of C2-C3-C4 domains, are 117 
evolutionarily more ancient than the four-domain IgG-Fc. IgE-Fc resembles the (C2-C3-C4)2 Fc 118 
structure of IgM, the most primitive antibody class, and the (C2-C3-C4)2 Fc domains of avian 119 
IgY, the ancestor of IgE and IgG [26]. The hinge region of IgG appears to have evolved to take the 120 
place of the (C2)2 domain pair, since the C2 and C3 domains of IgG-Fc are most closely 121 
homologous to the C3 and C4 domains of IgE-Fc. IgM molecules, as pentameric or hexameric 122 
structures, are known to undergo conformational changes upon contact with antigen that 123 
dramatically alter the disposition of the Fab arms relative to the Fc region, as observed by electron 124 
microscopy (EM) [27]. Unliganded, the IgM molecules appear planar and “star-shaped”, while 125 
bound to the surface of antigens they form “table-like” structures with the Fab arms bent down and 126 
away from the Fc region. These observations are pertinent to discussion of the flexibility and 127 
conformational change in IgE that will follow. 128 
 129 
 130 
Antibodies 2018, 7, x FOR PEER REVIEW  4 of 44 
 
 131 
Figure 2. IgE-Fc is conformationally flexible. (a) Unbound IgE-Fc adopts an acutely bent 132 
conformation [34]. (b) IgE-Fc adopts a partially bent conformation when in complex with an 133 
omalizumab-derived Fab [35]. (c) Fully extended IgE-Fc conformation captured by aFab [36]. (d) 134 
IgE-Fc adopts a fully extended conformation when in complex with the 8D6 Fab that is more 135 
compact than the conformation shown in (c) [37]. In panels (a) – (d), IgE-Fc chain B is coloured grey 136 
while chain A is coloured cyan, orange, pink and blue, respectively. For clarity, the anti-IgE Fabs are 137 
not shown in panels (b) – (d).  138 
Expectations that IgE, with the additional domain pair, might adopt a more extended Y-shaped 139 
structure than that of IgG [28], were refuted by early biophysical studies of IgE in solution and when 140 
FcRI-bound that indicated a more compact conformation [29,30]. In particular, elegant work with 141 
IgE molecules fluorescently labelled in their antigen-binding sites and at the C-termini of their Fc 142 
regions, clearly indicated through fluorescence (Förster) resonance energy transfer (FRET) distance 143 
measurements that the IgE molecule was not extended, but bent [31,32]. This was later confirmed by 144 
small-angle X-ray scattering (SAXS) studies of IgE and IgE-Fc in solution, the latter indicating that 145 
the Fc itself was a compact structure, best modelled by folding the (C2)2 domain pair back onto the 146 
C3-C4 domains [33]. However, when the first X-ray crystal structure of the whole IgE-Fc was 147 
solved [34], the bend was found to be even more acute than that which had been modelled (Figure 148 
2a), with the C2 domain of one chain even contacting the C4 domain of the other; furthermore, by 149 
bending of the (C2)2 domain pair over towards one side of the (C3-C4)2 region, the IgE-Fc 150 
molecule adopted an asymmetrical three-dimensional structure, despite its symmetrical primary 151 
structure (chemical sequence). A FRET study of IgE-Fc further confirmed that this bent structure 152 
does indeed exist in solution [38]. Might IgE-Fc be able to “un-bend”, akin to the conformational 153 
changes that IgM appears to undergo? 154 
 155 
Despite the identical primary structures of the two heavy (and two light) chains, IgE, like IgG 156 
and all other antibody classes, is glycosylated [39-42], and since there is heterogeneity not only in the 157 
pattern of glycosylation at the various potential sites but also in the composition at any particular 158 
site, the two heavy chains within any one IgE (or IgG) molecule are not precisely identical. Whether 159 
or not this compositional asymmetry is related to the asymmetric bending of the IgE-Fc has not been 160 
explored. One glycosylation site is conserved across all antibody classes: Asn394 in the C3 domain 161 
of IgE, structurally homologous to Asn297 in the C2 domain of IgG. Other potential sites in the C2 162 
and C3 domains are not always fully glycosylated, but Asn394, like its homologues in other 163 
antibody classes, is always fully occupied [39-41]. The branched carbohydrate chains occupy space 164 
between the C3 domains, as they do between the C2 domains of IgG, but there is a major difference 165 
between IgE and IgG in this respect: the glycosylation at Asn394 in IgE is of the “high-mannose” 166 
type, in contrast to the “complex-type” at Asn297 in IgG (Figures 1c and 1d). Other glycosylation 167 
sites in IgE that are exposed at the surface are complex-type, which suggests that the high-mannose 168 
composition at Asn394 may be due to the C2 domains impeding access of the mannosidase 169 
enzymes responsible for trimming the high-mannose structures prior to assembly of the 170 
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complex-type glycoforms. The same high-mannose structure is seen in IgY-Fc between the C3 171 
domains [43], perhaps similarly due to the presence of C2 domains. The high-mannose, branched 172 
carbohydrate chains in IgE-Fc not only make non-covalent (hydrogen bond, hydrophobic and van 173 
der Waals) contacts with the C3 domains to which they are covalently attached, and to the adjacent 174 
C4 domains, but also make contact with each other, bridging the two heavy chains [25,34,44]. 175 
Despite this apparent structural role, and again in contrast to IgG in which loss of glycosylation at 176 
Asn297 compromises FcR binding [45], both FcRI and CD23 receptor-binding activity is 177 
maintained in the absence of glycosylation; IgE-Fc expressed in bacteria and refolded [46,47], or 178 
deglycosylated following mammalian expression [48,49], binds to both receptors. However, 179 
glycosylation at Asn394 is essential for expression of functional IgE in mammalian cells in vitro and 180 
in vivo [41,50].  181 
 182 
IgE thus differs in important ways from IgG, not only in terms of its overall structure and, as 183 
will now be discussed, its flexibility, but also with respect to the nature and the role of its 184 
glycosylation. 185 
 186 
3. Conformational dynamics in IgE-Fc 187 
Crystal structures of the sub-fragment of IgE-Fc consisting of only the C3 and C4 domains, which 188 
we term Fc3-4, and IgE-Fc, have revealed a degree of flexibility in the arrangement of the C3 189 
domains relative to each other, either further apart (“open”) or closer together (“closed”) 190 
[25,34-37,44,51-59]. Furthermore, unliganded IgE-Fc structures were only bent (Figure 2a) [25,34,44]. 191 
It was therefore a considerable surprise to discover that in the crystal structure of the first complex 192 
between IgE-Fc and an anti-IgE antibody Fab, aFab, the Fc had adopted a fully extended 193 
conformation (Figure 2c) [36]. Further analysis revealed that the anti-IgE Fab, which binds at the 194 
C2/C3 interface in a 2:1 complex with IgE-Fc, was selecting a pre-existing conformational state of 195 
the molecule in solution, and thus the question arose: if IgE-Fc could spontaneously “un-bend” to 196 
reach a fully extended state, could the (C2)2 domain pair then “flip over” to lie in a bent 197 
conformation on the other side of the Fc3-4 region? In order to estimate the energetics of this 198 
potential “flipping” of the IgE-Fc, extensive molecular dynamics (MD) simulations were carried out 199 
[36]. It was discovered that the bent structure lies in a relatively deep energy well, but that once the 200 
IgE-Fc molecule had escaped this minimum, the “conformational landscape” was relatively flat, i.e. 201 
there were no significant barriers to prevent it reaching the extended conformation or indeed 202 
allowing the (C2)2 domains to bend over onto the other side of the molecule. The MD simulations 203 
revealed that this flipping of the C2 domains required the C3 domains to open somewhat, but the 204 
rate-limiting step for the process was clearly escape from the energy well representing the bent 205 
conformation. Most molecules would be in the bent state at any given time, consistent with the SAXS 206 
and FRET data in solution, but occasionally they flip over, although the rate and frequency of this 207 
event is difficult to assess. 208 
 209 
Anti-IgE antibodies of the IgG class, such as aFab, directed against the Fc region clearly have 210 
potential as anti-allergy therapeutics if, by either steric or allosteric means, they inhibit FcRI or 211 
CD23 engagement. These activities will be discussed in the following two sections, and we first 212 
concentrate here on the lessons learned about IgE flexibility from structural studies of these anti-IgE 213 
Fab/IgE-Fc complexes. Omalizumab is a clinically approved anti-IgE antibody, and it binds to a 214 
partially bent conformation, intermediate between the bent and extended structures (Figure 2b) [35]. 215 
It binds to the C3 domains, also in a 2:1 complex, and causes the C3 domains to move further apart 216 
and adopt a very “open” conformation. Another anti-IgE antibody, termed 8D6, directed to the C2 217 
and C3 domains, binds to a fully extended IgE-Fc conformation (rather like aFab, Figure 2c) but in 218 
the 8D6 structure (Figure 2d) the (C2)2 domain pairs are twisted and compressed towards the C3 219 
domains, as in a corkscrew motion [37]. To date, these are the only structures that have been 220 
published for IgE-Fc in complex with anti-IgE Fabs (Figure 3).    221 
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Figure 3. Crystal structures of IgE-Fc in complex with anti-IgE Fabs. (a) IgE-Fc in complex with an 223 
omalizumab-derived Fab [35]. (b) aFab/IgE-Fc complex [36]. (c) 8D6 Fab/IgE-Fc complex [37]. In 224 
panels (a) – (c), IgE-Fc chain B is coloured grey while chain A is coloured orange, pink and blue, 225 
respectively. The Fab heavy and light chains are coloured in wheat and pale yellow, respectively. 226 
 227 
 The picture that emerges from these structural studies is that of a highly flexible Fc region in 228 
which the C2 domains are capable of extending and twisting relative the Fc3-4 region, or bending  229 
over to either side, with the C3 domains adopting closed or open states. With regard to the 230 
flexibility of the whole IgE molecule, i.e. that of the Fab arms relative to the Fc, we lack 231 
crystallographic data, although molecular simulations suggest that the short C1-C2 linker of only 232 
five or six amino-acids substantially restricts the available conformations compared with the Fab 233 
arm flexibility mediated by the hinge regions in IgG subclasses [36,38]. This is consistent with earlier 234 
biophysical studies in solution which showed less Fab arm flexibility in IgE compared with IgG [60]. 235 
Nevertheless, despite lacking an IgG-like hinge, the linker between the C2 and Cε3 domains can 236 
clearly permit bending of the whole IgE molecule, just as is seen in IgM with its (C2)2 domains and 237 
no hinge [27], although in IgM the precise nature of the bending remains unresolved. 238 
 239 
4. IgE-receptor interactions 240 
The structural details of IgE binding to the soluble extracellular domains of both FcRI and CD23 are 241 
now well established. FcRI expressed on mast cells and basophils comprises four polypeptide 242 
chains, 2 (Figure 4a), but on other cell types it lacks the -chain, which may serve either as an  243 
“amplifier” of down-stream signalling, since the -chain contains an additional copy of the 244 
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 246 
Figure 4. FcRI (a) Schematic representation of FcRI: the four chains are indicated, showing the two 247 
extracellular Ig-like domains of the -chain that contain the IgE-binding activity, and the locations of 248 
the three intracellular ITAM signalling motifs. Figure adapted by permission from John Wiley & 249 
Sons, Inc. [Sutton, B.J.; Davies, A.M. Structure and dynamics of IgE-receptor interactions: FcεRI and 250 
CD23/FcεRII. Immunol. Rev. 2015, 268, 222-235 [6]]. (b) IgE-Fc adopts an acutely bent conformation 251 
when in complex with sFcRI, engaging the receptor (purple) at two distinct sub-sites [44]. IgE-Fc 252 
chains A and B are coloured dark cyan and pale cyan, respectively.   253 
 254 
immuno-tyrosine activation motif (ITAM) present in the -chains, or it may affect surface expression 255 
[7]. All of the IgE-binding activity resides in the two Ig-like domains of the -chain, termed sFcRI, 256 
the only substantial extracellular part of the receptor (Figure 4a). The crystal structure of sFcRI 257 
bound to Fc3-4 first revealed the 2 domain and part of the 1-2 linker bound across the two C3 258 
domains, close to the point of connection to the C2 domains [56]. When the structure of the complex 259 
with the complete IgE-Fc was solved, contrary to expectations that the Fc might unbend, the angle 260 
was found to become even more acute (from 62 to 54; Figure 4b) [44]. This enhanced bend seen in 261 
the crystal structure with IgE-Fc agrees not only with a recent study in solution with a FRET-labelled 262 
IgE-Fc molecule [38], but also, strikingly, with the work carried out more than 25 years ago with 263 
FRET-labelled IgE bound to FcRI on cells, which showed a more compact structure for IgE when 264 
receptor-bound than in solution [32]. This orientation of IgE and acutely bent Fc, as indicated in 265 
Figure 4b, places constraints upon the disposition of the Fab arms, which may well be critical for 266 
understanding how the IgE molecule engages both FcRI on cells and antigen (allergen), whether 267 
soluble or on a target cell, to enable receptor cross-linking and effector cell activation. These 268 
topological issues will be considered in more detail below.  269 
 270 
CD23 is a homo-trimeric type-II membrane protein with its C-terminal C-type lectin-like 271 
“head” domains, to which IgE binds, spaced from the membrane by a triple -helical coiled-coil 272 
“stalk” (Figure 5a). There is also a C-terminal “tail” of unknown structure that is required for 273 
binding to CD21, a co-receptor for CD23, engagement of which is implicated in B cell activation and 274 
cell adhesion events [4,6,61-63]. We will focus on the IgE/CD23 interaction. The crystal structure of a 275 
single lectin-like domain alone, lacking the stalk and tail, which we will term sCD23, binds to IgE-Fc 276 
with a 2:1 stoichiometry, although the affinities for the two sCD23 molecules differ by more than a 277 
factor of ten (Ka  106 M-1 and 105 M-1) [53]. The binding of both molecules can be seen clearly in 278 
Figure 5b, one sCD23 molecule bound to each -chain in a similar manner, principally to C3 but also 279 
contacting C4, in this complex with Fc3-4 [51]. However, the structure of sCD23 bound to IgE-Fc, 280 
which unexpectedly trapped only the first binding event (Figure 5c), explains the difference in 281 
affinity [53]. This 1:1 complex reveals how the first sCD23 molecule binds to an asymmetrically bent 282 
IgE-Fc, principally to C3 as before and also to C4, but with a single hydrogen bond and some van 283 
der Waals contacts with a C2 domain; the (C2)2 domain pair remains essentially bent, but swings  284 
 285 
Antibodies 2018, 7, x FOR PEER REVIEW  8 of 44 
 
 286 
Figure 5. CD23. (a) Schematic representation of CD23: the three identical chains showing the triple 287 
-helical coiled-coil “stalk”, C-type lectin-like IgE-binding “head” domains, and C-terminal “tails”. 288 
Figure adapted by permission from John Wiley & Sons, Inc. [Sutton, B.J.; Davies, A.M. Structure and 289 
dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol. Rev. 2015, 268, 222-235 [6]]. 290 
(b) The 2:1 complex between sCD23 (orange) and Fc3-4 [51]. (c) The 1:1 complex between sCD23 291 
(orange) and IgE-Fc, in which IgE-Fc adopts an acutely bent conformation [53]. In panels (b) and (c), 292 
IgE-Fc chains A and B are coloured dark cyan and pale cyan, respectively.  293 
about 16 to accommodate CD23 binding (Figure 5c) [53]. The site for the second CD23 head is 294 
completely accessible, although not occupied in this crystal structure, but this asymmetry of the two 295 
-chains explains the difference in affinity at the two CD23 binding sites. 296 
 297 
As expected for a “C-type” lectin domain there is a Ca2+ binding site, although IgE binding does 298 
not require occupancy of this site [51,53,64]. Neither does this “lectin” interaction with IgE involve 299 
carbohydrate, although its binding to CD21 may be carbohydrate-dependent. In the presence of Ca2+, 300 
IgE binding is enhanced [62], 30-fold at 37C, through ordering of a loop and a subtle conformational 301 
change that enables additional contacts with IgE [54]. Intriguingly, these additional contact residues 302 
comprise a second Ca2+ binding site in murine CD23, an indication perhaps of a step in the evolution 303 
of the interaction of IgE with this C-type lectin domain. The Ca2+ dependence of the affinity, 304 
undoubtedly enhanced in the context of the trimer through an avidity effect, may be functionally 305 
important for unloading of IgE/allergen complexes by CD23 in endosomes, where the Ca2+ 306 
concentration is two to three orders of magnitude lower than at the cell surface, prior to CD23 307 
recycling to the cell surface [65,66]. 308 
 309 
It is important to realise that although IgE can bind to two CD23 heads, these cannot belong to 310 
the same CD23 trimer; the N-termini of the two sCD23 molecules, which connect to the stalk (Figure 311 
5b), are so far apart that most of the stalk would have to unravel for this to be possible [51]. 312 
However, IgE can cross-link two membrane CD23 trimers, and soluble trimeric forms of CD23 313 
containing both head and stalk can cross-link membrane IgE (on B cells committed to IgE synthesis) 314 
or soluble IgE; in all of these cases, the bivalence of IgE and trivalence of CD23 can combine to create 315 
large complexes, which may be required for signalling in the context of B cell or APC activation [4].  316 
 317 
 318 
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 319 
Figure 6. Binding of IgE to its receptors is allosterically regulated. (a) sFcRI (purple) binds to the 320 
Fc3-4 region when the C3 domains adopt an open conformation [44]. (b) sCD23 (orange) binds to 321 
the Fc3-4 region when the C3 domains adopt a closed conformation [51]. In panels (a) and (b), 322 
IgE-Fc chains A and B are coloured dark cyan and pale cyan, respectively. 323 
 324 
5. IgE – an allosteric antibody 325 
The crystal structures of the two receptor complexes reveal a key element of the IgE molecule, 326 
namely that there is allosteric communication between the two receptor-binding sites. It is known 327 
that IgE cannot bind to both receptors simultaneously [67,68], and vital that this is so, since 328 
otherwise trimeric CD23 could cross-link FcRI-bound IgE on mast cells or basophils, causing 329 
activation and an inflammatory response in the absence of allergen. Indeed, binding of sFcRI 330 
inhibits sCD23 binding, and vice versa [51,69]. Earlier it was thought that the two binding sites must 331 
overlap, but we know now that although both lie principally within C3, they are far apart from each 332 
other at opposite ends of the domain (Figures 4, 5 and 6). This mutual inhibition is achieved 333 
allosterically [51,69], mainly through changes in the disposition of the C3 domains relative to the 334 
C4 domains. To engage FcRI, the C3 domains must adopt an “open” state (Figure 6a), which 335 
changes the angle between the C3 and C4 domains and prevents binding of CD23 at the C3/C4 336 
interface. However, when CD23 binds, the C3 domains move closer together and this more 337 
“closed” conformation precludes FcRI binding (Figure 6b).  338 
 339 
Not only do the C3 domains undergo these domain motions, but they also appear to have 340 
evolved a high degree of intrinsic flexibility; when compared with other immunoglobulin domains 341 
in terms of hydrophobic core volume or other indicators of dynamics, C3 is clearly an outlier, and 342 
when expressed as an isolated domain it has been described as adopting a “molten globule” rather 343 
than a fully folded state [25,70-74]. Plasticity at the IgE-Fc/CD23 interface [55,75] and ordering of C3 344 
upon FcRI binding [70] has been observed, with entropic contributions to the thermodynamics 345 
and kinetics of receptor binding playing an important role [44]. Remarkably, one of the earliest 346 
biophysical studies of IgE, not long after its discovery, identified the C3 domains as the most 347 
sensitive region of the molecule to heat denaturation [76], and this lability of C3 may in fact be 348 
critical for IgE’s unique receptor-binding properties and inter-site allosteric communication.  349 
 350 
Allosteric effects in IgE-Fc were also observed when the mode of action of the anti-IgE 351 
omalizumab was elucidated through determination of the structure of the complex and studies in 352 
solution [35]. It was discovered that omalizumab binding to IgE-Fc not only “unbends” the molecule 353 
as described above (Figure 2b), but causes the C3 domains to move so far apart that they cannot 354 
engage FcRI, thus allosterically inhibiting FcRI binding while simultaneously inhibiting CD23 355 
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binding orthosterically. Allostery and the conformational dynamics of IgE-Fc lie at the heart of a 356 
potentially even more important phenomenon concerning inhibition of FcRI binding, namely the 357 
observation that it is possible for omalizumab not only to bind to free IgE and block binding to the 358 
receptor, but also to bind to receptor-bound IgE and facilitate its dissociation [35,77,78]. First 359 
reported with another IgE-Fc binding protein, a Designed Ankyrin Repeat Protein or Darpin [79], 360 
the ability of omalizumab to bind to FcRI-bound IgE and cause it to dissociate was a most 361 
unexpected result, but one with exciting clinical potential. Although this “accelerated dissociation” 362 
occurs only at very high concentration, above therapeutic levels of omalizumab [35,77], the 363 
explanation for this phenomenon lies in the fact that even when bound to FcRI, IgE-Fc displays an 364 
ensemble of conformations; binding omalizumab alters the composition of this ensemble, reducing 365 
the energy barrier to IgE/FcRI dissociation [35]. The intrinsic flexibility and allosteric properties of 366 
IgE can thus be exploited therapeutically to actively remove IgE from FcRI. 367 
 368 
Two other anti-IgE antibodies have been found to exploit allosteric effects. MEDI4212 inhibits 369 
FcRI binding orthosterically and CD23 binding allosterically, the latter by locking the C3 domains 370 
in an open conformation [52]. Antibody 8D6, which extends the IgE-Fc as described above (Figure 371 
2d), inhibits FcRI binding both orthosterically and allosterically but does not affect the CD23 372 
interaction [37]; this may prove valuable therapeutically for allergic disease if down-regulation of 373 
IgE production can be effected through the interaction of 8D6/IgE complexes with mCD23 on B cells. 374 
The 8D6 antibody demonstrates that selective inhibition of IgE binding to its two principal receptors 375 
is possible.   376 
6. Antigen (allergen) binding 377 
So far we have focussed on the Fc region of IgE and its receptor interactions. The binding of IgE to 378 
antigens, and in particular to allergenic proteins, has been studied in detail with antibody Fab 379 
fragments, but the flexibility of the IgE molecule as a whole, and in particular its ability to engage 380 
both allergen and its receptors, can only currently be inferred from low resolution electron 381 
microscopy (EM) studies and modelling; there are no high resolution structural data for intact IgE. 382 
EM studies of IgE complex formation with anti-idiotype IgG molecules have shown a relatively 383 
restricted degree of Fab arm flexibility [80], and a recent EM analysis of immune complex formation 384 
with IgE molecules binding to IgE epitopes grafted onto a small protein (myoglobin) framework, 385 
showed that the relative disposition, and in particular the proximity of the epitopes, affected 386 
immune complex formation and their ability to activate effector cells [81]. Modelling of Fab arm 387 
flexibility within the FcRI-bound IgE molecule confirmed this view that the relatively restricted 388 
range of dispositions of the Fabs, together with the particular geometrical arrangement of the 389 
epitopes on the allergen, might be key to an allergen’s potency in effector cell activation [36,38]. 390 
Other important requirements for a potent cellular response, in addition to epitope specificity, are 391 
affinity and the particular combination of antibodies present [82].  392 
 393 
There are now several crystal structures of antibody Fabs binding to their specific epitopes on 394 
protein allergens, although most are murine IgG antibodies raised against the allergen [83-90]; not 395 
all of these may represent epitopes recognised by allergic patients’ IgE antibodies. Two studies 396 
generated IgE Fabs by phage display using combinatorial libraries derived from patients allergic to 397 
either the milk protein -lactoglobulin (Bos d 5) [91] or the grass pollen allergen Phl p 2 [92], although 398 
these almost certainly do not consist of the “natural” VH-VL pairing that occurred in the patient. A 399 
recent study generated a naturally paired VH-VL combination by single B cell cloning of an IgG4 400 
antibody from an allergic patient undergoing immunotherapy with the grass pollen allergen Phl p 7; 401 
this antibody was converted to an IgG1 Fab for the crystal structure analysis of the complex with 402 
allergen, and to IgE for functional analyses [23]. In all of these studies, the allergens were recognised 403 
by the antibodies in a conventional manner, involving many if not all of the CDRs. However, the 404 
most recent study also revealed an additional, unconventional “superantigen-like” interaction 405 
 406 
Antibodies 2018, 7, x FOR PEER REVIEW  11 of 44 
 
 407 
Figure 7. Crystal structures of allergens cross-linking two identical antibody Fab arms. (a) Dimer of 408 
allergen Bos d 5 (monomeric subunits coloured yellow and olive green) recognised classically by two 409 
identical Fab molecules (VH and VL domains indicated) [91]. (b) As a), orthogonal orientation [91]. (c) 410 
Two monomeric molecules of allergen Phl p 7 (coloured green), each independently recognised by 411 
two identical Fab molecules (VH and VL domains indicated) [23]. (d) As c), orthogonal orientation, in 412 
which only one of the two Phl p 7 molecules can be seen, recognised classically by the Fab on the 413 
right, and in a superantigen-like manner by the Fab on the left [23]. 414 
between Phl p 7 and the antibody, involving amino-acid residues of the VL framework region (FR) 415 
[23]. 416 
 417 
The allergen/antibody structures involving conventionally recognised epitopes demonstrate 418 
how an allergen that can dimerise, such as Bos d 5 [91], could cross-link two identical IgE antibodies 419 
(Figures 7a and 7b) and, if FcRI-bound, lead to mast cell or basophil activation. A similar structure 420 
was seen in the complex of two identical Fabs bound to a dimer of the cockroach allergen Bla g 2 [86]; 421 
this allergen in monomeric form can however cross-link two antibodies that recognise epitopes on 422 
opposite faces of the allergen [93], and a similar topology arises for two different antibody Fabs that 423 
bind non-overlapping epitopes on monomeric house dust mite allergen Der p 1 [89]. The 424 
non-conventional, partly FR-mediated recognition of Phl p 7 by an allergic patient’s antibody, 425 
occurring at the same time as conventional CDR-mediated recognition (Figures 7c and 7d), shows 426 
that certain allergens can cross-link identical IgE molecules using this alternative mechanism [23]. B 427 
cell superantigens, such as Staphylococcus aureas Protein A or Peptostreptococcus magnus Protein L, 428 
cross-link antibodies by interacting with their FRs, and thus molecules that cross-link IgE in this 429 
way, such as Protein L, have been termed “superallergens” [94]. Phl p 7 thus displays 430 
“superallergen-like” behaviour, which may contribute to the potency of particular allergens. 431 
Intriguingly, a structure of the monomeric cat allergen Fel d 1 in complex with an IgG Fab that blocks 432 
human IgE binding [90] shows a FR-mediated contact in the crystal which, together with the 433 
CDR-mediated interaction, could cross-link two identical Fabs in a manner very similar to that 434 
depicted for Phl p 7. 435 
 436 
Activation of mast cells or basophils by cross-linking FcRI-bound IgE may thus be envisaged 437 
as shown in Figure 8. The regions of space accessible to the two Fab arms appear to be more 438 
restricted and almost non-overlapping when IgE is bound to receptor: one arm points “parallel” to 439 
the membrane while the other points away [36,38]. These topological constraints may need to be 440 
considered when IgE is used to target cell surface antigens, rather than soluble allergens, to allow 441 
simultaneous engagement with FcRI on effector cells.      442 
 443 
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 444 
Figure 8.  Schematic representation of FcRI-bound IgE cross-linking by soluble allergen. A dimeric 445 
allergen (green) engages two identical IgE antibodies (blue and orange domains) that are bound by 446 
the C3 domains (C4 domains not shown) to the extracellular 1 and 2 domains of FcRI (purple). 447 
This is representative of the structure shown in Figures 7a and 7b; a monomeric allergen could 448 
similarly cross-link two identical IgE molecules as shown in Figures 7c and 7d, or two different 449 
antibodies recognising non-overlapping epitopes. The restricted flexibility of the Fab arms in 450 
receptor-bound IgE may mean that the other arm is important for engagement of cell surface 451 
antigens.        452 
 453 
7. Rationale for harnessing IgE-mediated functions against cancer 454 
IgE is clearly a powerful activator of the immune system by virtue of the Fc receptor interactions 455 
described above, potentiating effector functions and antigen presentation; even well below receptor 456 
saturation levels, tissue-resident immune cells such as mast cells and macrophages enable this 457 
antibody isotype to exert long-lived and powerful immune surveillance in tissues such as the gut, 458 
skin, epithelial and mucosal surfaces. In addition to its contributions to the pathogenesis of allergic 459 
diseases and anaphylactic reactions, IgE plays a physiological role in immune protection against 460 
parasites, triggering inflammatory cascades that cause vasodilation and local enhancement of 461 
protective responses in conjunction with antibodies of other isotypes [95-97]. These latter, less 462 
well-described, attributes of IgE may be of potential significance to applications in cancer 463 
immunotherapy.  464 
 465 
7.1. Epidemiological links between IgE, allergy and cancer 466 
The concept of a role for IgE in conferring immune protection against cancer dates back many 467 
decades, with early studies providing evidence for a role of allergic responses in restricting tumour 468 
xenograft growth in mice, negative correlations between atopy and cancer [98-102], and decreased 469 
prevalence of immediate hypersensitivity in patients with cancer [103]. Immunohistochemical (IHC) 470 
evaluations on head and neck cancer showed that IgE-expressing cells were more abundant in 471 
tumours compared with normal mucosa [104], and a pancreatic cancer patient-derived IgE antibody 472 
could potentiate anti-tumour effector functions [105]. Certain conditions and stimuli that cause 473 
epithelial damage and stress signals may lead to the induction of an adaptive immune response 474 
favouring B cell class switching to IgE, which can restrict cancer growth. Such protective functions 475 
have been reported following local exposure of skin to environmental DNA-damaging stress signals, 476 
which triggered adaptive immune responses and production of IgE antibodies that conferred 477 
protection from epithelial carcinogenesis [106]. Subsequent findings of inverse associations between 478 
allergic or atopic status and protection from cancer varied significantly. Inverse associations of 479 
allergic or atopic disease with the risk of developing specific malignancies including glioma, 480 
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pancreatic cancer, lymphatic/hematopoietic, gastrointestinal, skin and gynaecological origin 481 
tumours have been reported [107-111], although significant limitations of such studies include 482 
reliance of self-reported symptoms of allergy and lack of specific measurable biomarkers. More 483 
recent studies examined eosinophil counts and skin prick test positivity, as well as titres of IgE and 484 
allergen-specific IgE, with some reporting reduced risk of developing specific cancers, and reduced 485 
risk of developing cancer overall [110-113]. Although taken together, epidemiological reports point 486 
to complex relationships between allergies, IgE levels and carcinogenesis, tantalising evidence also 487 
supports a functional role for IgE as a passive or active component in anti-tumour responses.  488 
 489 
7.2. Features of IgE that may translate to immune protective functions against tumours 490 
To date, therapeutic monoclonal antibodies designed for the treatment of cancers are typically 491 
engineered with Fc regions belonging to the IgG isotype. IgG1 is typically chosen when effector 492 
functions are required, while IgG4 is preferred when Fc-mediated attributes are not desired. 493 
However, until recently, antibodies of other isotypes such as IgE or IgA had never been tested in 494 
humans [114-116].  495 
 496 
In our studies we hypothesised that several unique attributes of IgE could form a powerful 497 
immunological profile suitable for immunotherapy of solid tumours such as ovarian carcinomas 498 
[117]. These include high affinity for cognate receptors on a different set of immune cells to those 499 
engaged by IgG, long tissue residency and immune surveillance, ability to potentiate strong effector 500 
functions at relatively low levels of Fc engagement with effector cells, and lack of inhibitory Fc 501 
receptors. 502 
 503 
High affinity for cognate receptors: The affinity of IgE for FcεRI is typically 100- to 10,000-fold 504 
higher than those of the clinically used IgG isotypes for their Fcγ receptors. Additionally, the avidity 505 
of IgE for trimeric CD23 is comparable to that measured with IgG-FcγRI complexes. These 506 
properties mean that IgE can persist on immune cells in the absence of antigen complex formation. If 507 
IgE antibodies are directed against cancer antigens, these features could be highly beneficial in 508 
ensuring potent effector functions, long persistence and immune surveillance at tumour sites. 509 
 510 
Lack of inhibitory Fc receptors: IgE antibodies have no known inhibitory Fc receptors to moderate 511 
effector functions. This contrasts with IgG, which is subject to control by the inhibitory receptor, 512 
FcγRIIb, known to be upregulated in the tumour microenvironment (TME) of different cancer types. 513 
Lack of an inhibitory FcεR may mean that IgE is not subjected to suppressive influences imposed on 514 
IgG by tumours. 515 
 516 
Long immune surveillance in tissues: The half-lives of IgE and IgG antibodies vastly differ in the 517 
circulation and tissues: 1.5 days for IgE and 2-3 weeks for IgG in the serum, partly due to the lack of 518 
FcRn binding by IgE. The opposite is true in tissues such as the skin, where the half-life of IgE is 519 
approximately 2 weeks compared with 2-3 days for IgG [118,119]. Long tissue residency and 520 
immune surveillance in the presence of FcR-expressing effector cells, may have potential benefits if 521 
directed against cancers. These may include epithelial and skin tumours such as malignant 522 
melanomas, squamous cell and ovarian carcinomas. 523 
 524 
Presence of IgE immune effector cells in tumours: The inflammatory milieu of the TME may include 525 
FcεR-expressing immune effector cells such as monocytes, macrophages, mast cells, dendritic cells 526 
(DCs) and eosinophils. Although pro-tumoural or tumour-tolerant subsets of these cells may lack 527 
the ability to mount an anti-tumour attack, it is possible that cells armed by tumour antigen-specific 528 
IgE tightly bound on FcεRs could overcome tolerant phenotypes. 529 
 530 
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Fc-mediated effector functions: IgE can potentiate a range of effector functions through 531 
engagement of FcεRI and CD23. These include: antibody-dependent cell-mediated cytotoxicity 532 
(ADCC) by immune cell types including monocytes, macrophages, eosinophils and mast cells, with 533 
release of toxic mediators (e.g. nitric oxide), proteases, cytokines and chemokines (e.g. tumour 534 
necrosis factor, TNFα, macrophage chemoattractant protein-1, MCP-1) associated with target cell 535 
lysis; antibody-dependent cell-mediated phagocytosis (ADCP) by macrophages and monocytes; 536 
mast cell and basophil degranulation leading to the release of proinflammatory mediators, and 537 
enhancement of immune cell recruitment and activation at the antigen challenge sites (Figure 9). 538 
These attributes could result in enhanced immune cell recruitment, surveillance and anti-tumour 539 
functions.  540 
 541 
Exerting anti-parasite effector functions: The physiological roles of IgE in protective immune 542 
responses against parasites are well-documented. Anti-parasitic IgE and IgE loaded on effector cells 543 
such as eosinophils have been shown to confer protection against different parasites (e.g. Schistosoma 544 
mansoni) [121]. IgE engaged with FcεRI or CD23 can engender parasite clearance by human 545 
eosinophils, platelets and macrophages through ADCC and ADCP [122,123]. Furthermore, high 546 
serum titres of parasite antigen-specific IgE have been associated with resistance to infection 547 
[124,125]. Macrophages, eosinophils and mast cells have all been reported to be involved in these 548 
protective mechanisms [5,97,123,126,127]. IgE-mediated immune clearance of large parasites in 549 
tissues, including Th2-biased environments such as the gut, draws parallels with conditions in solid 550 
tumours in which a similar Th2 inflammatory milieu and the presence of immune cells such as 551 
macrophages may form appropriate environments in which IgE could act to eradicate tumours by 552 
similar mechanisms. 553 
 554 
Overcoming antibody blockade mechanisms associated with Th2-biased tumour conditions: 555 
Tumour-associated production of alternatively-activated (e.g. IL-10-driven) rather than 556 
classically-activated (IL-4-driven) Th2 environments may support local antibody class switching to 557 
inflammatory and immunologically inert isotypes such as IgG4. Th2-biased inflammatory states that 558 
favour B cell class switching to IgG4 have long been identified in IgG4-related diseases characterised 559 
by chronic inflammation, circulating IgG-positive plasmablasts and high infiltration of 560 
IgG4-producing plasma cells in various tissues [128-130]. Alternative Th2 activation states have also 561 
been reported in several solid tumour types including pancreatic cancer, extrahepatic 562 
cholangiocarcinoma, melanoma and non-small cell lung cancer [131-135]. These pathological 563 
conditions, likely to be promoted by a combination of a Th2-biased inflammatory milieu and long 564 
antigen exposure, may signify that immune responses are driven away from the classical Th2-based 565 
class switching to IgE, in favour of IgG4. Evidence points to IgG4 antibodies not only being 566 
immunologically inert, but importantly being able to impair the immune-activating functions of 567 
otherwise cytotoxic IgG1 antibodies [135,136]. Numerous mechanisms may be at play, including 568 
competition for FcγR engagement with other IgGs, Fab arm exchange, and signalling though 569 
inhibitory Fc receptors, all supporting immunosuppressive signals [131,137]. The latter could have 570 
implications not only for modulating the endogenous humoral immune response but also for 571 
restricting the potency of IgG1 therapies. These regulatory mechanisms may offer opportunities to 572 
design anti-tumour IgE antibodies that function through a different Fc receptor, which could be less 573 
prone to the immunosuppressive signals that impair IgG functions against cancer. 574 
 575 
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 577 
Figure 9. IgE functions against cancer cells. IgE can potentiate Fc-mediated effector functions by 578 
engaging cognate receptors on immune effector cells such as monocytes, macrophages, neutrophils, 579 
eosinophils, basophils and mast cells. Antibody-dependent cell-mediated cytotoxicity (ADCC), and 580 
degranulation can result in the release of various toxic and pro-inflammatory mediators, including 581 
proteases, cytokines, chemokines, and histamine, which, together with antibody-dependent 582 
cell-mediated phagocytosis (ADCP), can result in enhanced anti-tumour functions and immune cell 583 
recruitment. IgE can also engage APCs to enhance antigen uptake and presentation. Like anti-cancer 584 
IgG antibodies, IgE may also exhibit direct effects against cancer cells, such as receptor dimerisation 585 
inhibition and reductions in cancer cell growth signalling. Figure adapted by permission from Taylor 586 
& Francis [Josephs, D.H. et al. IgE immunotherapy: a novel concept with promise for the treatment of 587 
cancer. mAbs 2014, 6, 54-72 [117]] and John Wiley & Sons, Inc. [Jensen-Jarolim, E. et al. 588 
AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy 2017, 72, 866-887 589 
[120]]. 590 
 591 
Engaging antigen presenting cells to stimulate effective adaptive immune response: IgE can engage 592 
with APCs to enhance antigen uptake and presentation to cognate T cells (Figure 9). IgE engagement 593 
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with FcεRI can cross-present antigen, priming a cytotoxic T lymphocyte (CTL) response [138,139]. 594 
Through such mechanisms, IgE has been reported to confer protective anti-tumour immunity and 595 
trigger memory responses. These antigen presentation-boosting attributes could be important in the 596 
TME where the functions and maturation of professional antigen presenting cells may be impaired. 597 
 598 
8. Pre-clinical studies of IgE antibodies targeting cancer antigens: the advent of AllergoOncology 599 
The development of immunologically active, antibody-based targeted therapies with potent 600 
Fc-mediated effector mechanisms has revolutionized the treatment of cancer patients with 601 
previously difficult to treat tumours [140]. A promising branch of this discipline is the emerging 602 
field of AllergoOncology, which focuses on Th2 and IgE-mediated immune responses in the cancer 603 
context [120,141-143]. Research in this field has opened the way for the development of IgE-based 604 
immunotherapy approaches, including monoclonal IgE antibodies as anti-cancer treatments 605 
[117,144]. 606 
 607 
The specific attributes of IgE described above, including natural immune activatory functions in 608 
tissues and high affinity for cognate receptors, have been proposed as a strategy for cancer 609 
immunotherapy. Antibodies engineered with IgE Fc regions, and designed to recognise 610 
tumour-associated antigens, may promote immune cell recruitment into tumours, and both direct 611 
and activate the Th2-biased immune stroma against cancer. Longer tissue-resident immune 612 
surveillance may then translate to anti-cancer efficacy. Therapeutic approaches have been developed 613 
to harness the immune-activating functions of IgE for cancer immunotherapy, including: IgE-coated 614 
cell vaccines, IgEs as adjuvants, vaccination approaches to trigger IgE-biased immune responses 615 
against tumour antigens, and recombinant IgE recognising tumour antigens. Here we will focus on 616 
the development of recombinant IgE antibodies [144]. Furthermore, we place specific emphasis on 617 
MOv18 IgE, as the first-in-class agent that has undergone extensive pre-clinical efficacy and safety 618 
evaluations in several model systems, prior to reaching clinical testing in patients with cancer. 619 
 620 
8.1. Engineering platforms for production of IgE antibodies for research and clinical translation 621 
Developing IgE antibodies that recognise cancer antigens relies on appropriate expression systems 622 
and protocols to facilitate antibody cloning and production. Since the development of hybridoma 623 
technology five decades ago, novel recombinant DNA technology, genetic manipulation and 624 
advances in cell biology have led to remarkable improvements in therapeutic recombinant antibody 625 
engineering [145]. Although significant efforts have focused on the optimization of expression 626 
platforms for IgG [146], relatively meagre investment has been directed towards engineering IgE. 627 
 628 
The study and clinical translation of IgE antibodies requires efficient and scalable production 629 
processes, but these have historically been characterised by low and variable yields. Despite this, 630 
several groups have shown that recombinant IgE antibodies can be produced using various cloning 631 
strategies. In early studies, restriction enzyme-based cloning methodologies were successfully 632 
employed using murine expression host cells to derive stable expression platforms, with Sp2/0 [147] 633 
and FreeStyleTM-293F [148] cell lines, reaching production yields in the range of 8-25 mg/L. 634 
Recombinant IgE antibodies have also been produced using transient expression platforms with 635 
human (HEK293T, FreeStyleTM-293F, Expi293FTM cells), insect- and plant-based systems, reaching 636 
yields of 30 mg/L [41,82,149,150]. More recent transient expression protocols have been 637 
implemented, which take advantage of Polymerase Incomplete Primer Extension (PIPE) cloning 638 
[151]. PIPE does not rely on restriction or other recombination sites, and can help expedite antibody 639 
cloning, a strategy that we have applied to IgE antibody production [152].  640 
  641 
We recently developed a highly-expressing stable recombinant IgE expression system for rapid 642 
production of functional antibody with features that allow scale-up for potential clinical evaluations 643 
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[153]. For this we implemented PIPE cloning and generated a vector containing the Ubiquitous 644 
Chromatin Opening Elements (UCOE) sequence located upstream of the transgene promoter to 645 
prevent promoter silencing. UCOE allows the expression of the transgene even if it is randomly 646 
integrated in a heterochromatin region [154]. This platform improves IgE yields to 87 mg/L per day, 647 
at least 33-fold higher production within 4 days compared with the best stable IgE expression system 648 
documented to date, and in small culture volumes of 25 mL with the potential for further scale-up 649 
production. 650 
 651 
These findings suggest that, as with IgG antibody production, IgE can be produced using a 652 
range of expression systems and with sufficient yields to facilitate functional evaluation and 653 
translation to clinical testing. Further efforts in the field promise to improve upon existing platforms 654 
for use in pre-clinical studies, process development, Good Manufacturing Practice (GMP) 655 
production and supply of material suitable for clinical studies. Other developments in antibody 656 
discovery such as knock-in mouse strains used to derive IgE antibodies by hybridoma techniques, 657 
phage display approaches using human antibody variable region repertoire libraries and single B 658 
cell cloning techniques may also be applicable [155-157]. 659 
 660 
Recombinant IgE antibody production has advanced significantly with several already 661 
engineered and tested in vitro and in vivo. There is however room for further development of 662 
improved and effective production systems that can be translatable to GMP environments and 663 
scale-up for clinical studies. 664 
 665 
8.2. Functional evaluations of anti-tumour IgEs 666 
8.2.1. In vitro and in vivo functional profiles of engineered IgEs targeting several cancer antigens 667 
Antibody engineering has yielded the first generation of IgE antibodies that have been studied in 668 
vitro and in vivo in numerous model systems. Anti-tumour IgE antibodies can engage various 669 
immune effector cells such as mast cells and basophils expressing high levels of tetrameric FcεRI 670 
(2), and monocytes and eosinophils that express trimeric FcεRI (2) at lower levels. Studies in 671 
vivo have been conducted in various mouse immunocompetent models. However, human IgE-Fc 672 
does not cross-react with mouse FcεR and, unlike in humans, mouse FcεRs are only expressed by 673 
mast cells and basophils, making the mouse immune system less suitable for the study of human IgE 674 
functions. However, transgenic mouse models have shown significant tumour-restricting abilities of 675 
IgE with human Fc domains. Examples of several monoclonal IgE antibodies evaluated over the last 676 
30 years are discussed below. 677 
 678 
A mouse IgE recognising the mammary tumour virus (MMTV) major envelope glycoprotein 679 
(gp36) was tested in an immunocompetent syngeneic mammary carcinoma. The antibody restricted 680 
the growth of subcutaneous (s.c.) mammary tumours compared with controls [158]. Another murine 681 
IgE recognising a colorectal cancer antigen (CCA) restricted the growth of a s.c. tumour in an 682 
antigen-specific and species-specific manner at concentrations far lower than those required for the 683 
equivalent IgG to engender the same effect [159]. A fully-human anti-HER2/neu IgE (C6MH3-B1 IgE) 684 
restricted the growth of intraperitoneal (i.p.) tumours compared to vehicle controls and prolonged 685 
the survival of human FcεRIα-transgenic mice [160]. The same agent was well tolerated when 686 
administered in cynomolgus monkeys, albeit at very low doses (up to 80 µg/kg). Another IgE 687 
specific for the epithelial tumour antigen MUC-1 restricted cancer growth when expressed locally in 688 
tumours along with chemoattractant mediators MCP-1 and IL-5 [161]. Furthermore, a mouse/human 689 
chimeric IgE antibody (clone AR47.47) recognising the prostate specific antigen (PSA) enhanced 690 
antigen presentation by DCs, and triggered CD4+ and CD8+ T cell responses. The same antibody 691 
complexed with its antigen prolonged the survival of human FcεRIα-transgenic mice subsequently 692 
challenged with prostate cancer cells [162]. 693 
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 694 
Human/mouse chimeric anti-HER2/neu IgE, and anti-EGFR (epidermal growth factor receptor) 695 
IgE, engineered from the original trastuzumab and cetuximab (IgG1) clones respectively, were 696 
shown to engender ADCC by human monocytic cells [163,164]. Specifically, anti-EGFR IgE triggered 697 
superior ADCC functions (70%) against cancer cells, compared with the corresponding IgG1 (30%) 698 
[164]. However, some episodes of anaphylaxis were observed in some patients with EGFR-positive 699 
tumours who received the anti-EGFR human/chimeric monoclonal IgG1 antibody cetuximab. These 700 
were caused by the presence of pre-existing IgE antibodies specific for the oligosaccharide 701 
galactose-α-1,3- galactose (α-Gal) on SP2/0-expressed cetuximab in a subset of individuals [165,166]. 702 
Furthermore, humans are known to carry IgG and IgM antibodies recognising α-Gal [167], and it is 703 
possible that these endogenous antibodies could have neutralised the anti-tumoural effects of 704 
cetuximab. Therefore, caution should be exercised in translating IgE class antibodies recognising 705 
EGFR on the grounds of safety and efficacy. An anti-human CD20 IgE triggered 706 
eosinophil-mediated ADCC and mast cell activation and killing of CD20-expressing tumour cells. 707 
Anti-HER2/neu, anti-EGFR, anti-CD20, anti-folate receptor alpha (FRα) IgE and anti-prostate specific 708 
antigen (PSA) IgE antibodies were all able to trigger rat basophil leukaemia (RBL) SX-38 mast cell 709 
degranulation when cross-linked in different ways including soluble antigen/polyclonal antibody 710 
complexes, cancer cells expressing multiple copies of the target antigen, and polyclonal anti-IgE. 711 
Furthermore, anti-HER2/neu (trastuzumab) IgE demonstrated the ability to exert direct effects on 712 
tumour cell viability in the absence of effector cells, equivalent to those reported to be triggered by 713 
trastuzumab IgG [163]. This supports the notion that anti-tumour IgE antibodies may be capable of 714 
engendering direct effects attributed to IgG equivalent agents, whilst perhaps still able to harness 715 
class-specific effector functions (Figure 9). 716 
 717 
The progress of the first-in-class monoclonal IgE antibody (MOv18) recognising a 718 
tumour-associated antigen to an early clinical trial in oncology is the exemplar advance in the field. 719 
Based on this development, herein we will focus on the evaluation and translation of this 720 
recombinant antibody, and efforts to translate IgE class therapeutic agents to clinical testing. If firstly 721 
safety, and secondly efficacy of this first-in-class agent could be demonstrated in the clinic, this will 722 
pave the way for further study and translation of the above-mentioned antibodies, as well as other 723 
novel anti-cancer antibodies of this class. 724 
 725 
 726 
8.2.2. MOv18 IgE, the first anti-tumour IgE to reach clinical testing: evaluation of in vitro effector 727 
functions 728 
An IgE antibody that has progressed to clinical testing is MOv18, a mouse/human chimeric 729 
monoclonal IgE antibody that recognises the tumour-associated antigen Folate Receptor alpha (FRα) 730 
(NCT02546921, www.clinicaltrials.gov). FRα is highly expressed in > 70% of ovarian carcinomas and 731 
other tumour types and has low and restricted expression distribution in normal tissues [168,169]. 732 
The IgG1 version of MOv18 has undergone early clinical trials as a therapeutic and imaging agent in 733 
patients with ovarian carcinomas, and treatment has been well tolerated [170-173]. FRα is considered 734 
a promising target for cancer therapy, with considerable evidence that either directing therapeutic 735 
antibodies to this receptor, or its inhibition by small molecules, is well-tolerated in man [174-178].  736 
 737 
In vitro, mouse/human chimeric MOv18 IgE activated human peripheral blood mononuclear 738 
cells (PBMCs) to kill ovarian cancer cells, compared with background cancer cell death with 739 
nonspecific mouse/human chimeric anti-4-hydroxy-3-nitro-phenacetyl (NIP) IgE, or no antibody 740 
controls [179]. Human monocytes were subsequently identified as important effector cells in 741 
PBMCs, based on live imaging studies in which IGROV1 ovarian cancer cells were found to contact 742 
one or more CD14-labelled human monocytes within 30 minutes of incubation of PBMCs and 743 
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IGROV1 cells together with MOv18 IgE. Phagocytosis of tumour cells was evident after 90 minutes 744 
of incubation, with IGROV1 cells becoming fragmented by 3 hours (Figure 10a).  745 
 746 
Following stimulation by IL-4, which is often released from IgE-sensitized basophils and mast 747 
cells, CD23 can be upregulated on monocytes, eosinophils and platelets. Interaction of IgE with 748 
CD23 may also have a role in ADCP of target cells by effector cells, as shown by its natural protective 749 
role in clearance of parasites. This function has also been described with MOv18 IgE. Human 750 
monocytes expressing FcεRI on the cell surface triggered IgE-mediated ADCC of tumour cells, while 751 
IL-4 stimulated monocytes killed FRα-expressing tumour cells by both ADCC and ADCP, compared 752 
to background levels of tumour cell death with NIP IgE and no IgE controls (Figure 10b). Specific IgE 753 
Fc receptor blockade studies in vitro confirmed that MOv18 IgE-dependent ovarian tumour cell 754 
killing had an ADCC component, primarily mediated by FcεRl. and an ADCP component, primarily 755 
mediated by CD23 [180,182]. 756 
 757 
The ability of MOv18 IgE to trigger functional degranulation was examined with RBL SX-38 758 
cells engineered to over-express the human tetrameric FcεRI. Exposure of the RBL SX-38 cells to 759 
MOv18 IgE alone did not induce significant degranulation; however cross-linking MOv18 IgE 760 
bound to the effector cell surface using either a polyclonal anti-IgE antibody or FRα-expressing 761 
cancer cells induced appreciable degranulation (Figure 10c) [181]. Eosinophils are key IgE effector 762 
cell types known to express low levels of FcεRI, but not CD23 [183]. Eosinophils mediated elevated 763 
ADCC (32.4%) with MOv18 IgE above isotype controls, and microscopical evaluations revealed 764 
contact between eosinophils and tumour cells, frequently accompanied by eosinophil degranulation, 765 
loss of tumour cell architecture, and apparent tumour cell death (Figure 10d) [182]. Our findings 766 
were consistent with data by Teo and colleagues who also reported the eosinophil-mediated ADCC 767 
functions by an anti-CD20 IgE antibody [161]. Interestingly, previous studies showed lack of 768 
eosinophil activation by IgE cross-linked with allergens. These differences could relate to the density 769 
of the target antigen. Tumour cells express very high numbers of tumour associated-antigens on 770 
their surface, crosslinking of which may be required to deliver an activatory signal through the 771 
lowly expressed FcεRI on eosinophils. However, this may not be the case for crosslinking of FcεRI by 772 
IgE complexed with multivalent allergens of much lower valency [184]. In the cancer context, the 773 
target antigen density could therefore be critical to triggering eosinophil-mediated anti-tumour IgE 774 
effector functions. 775 
 776 
These studies established that MOv18 IgE could mediate effector functions such as 777 
degranulation and tumour cell killing via both cytotoxicity (ADCC) and phagocytosis (ADCP) by 778 
activating known IgE effector cells. 779 
 780 
 781 
 782 
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Figure 10. In vitro evaluations of MOv18 IgE. (a) Live imaging studies showed contact between 785 
IGROV1 ovarian cancer cells and CD14-labelled human monocytes within 30 minutes of incubation 786 
of PBMCs and IGROV1 cells together with MOv18 IgE. Following 90 minutes, phagocytosis of 787 
tumour cells was evident and IGROV1 cells became fragmented by 3 hours [179]. Figure adapted by 788 
permission from John Wiley & Sons, Inc. [Karagiannis, S.N. et al. Activity of human monocytes in IgE 789 
antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 2003, 33, 790 
1030-1040 [179]]. (b) Human monocytes expressing cell-surface FcεRI triggered MOv18 791 
IgE-mediated ADCC of IGROV1 ovarian cancer cells, and IL-4 stimulated monocytes with 792 
up-regulated CD23 expression, killed tumour cells by both ADCC and ADCP compared to 793 
background levels mediated by non-specific NIP IgE and no IgE controls [180]. Figure adapted by 794 
permission from Springer Nature. [Karagiannis, S.N. et al. Role of IgE receptors in IgE 795 
antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. 796 
Cancer Immunol. Immunother. 2008, 57, 247-263 [180]]. (c) Appreciable degranulation of RBL SX-38 797 
cells was triggered by cross-linking of cell surface receptor-bound MOv18 IgE by polyclonal anti-IgE 798 
antibody (left) or FRα-expressing cancer cells (right) [181]. Figure adapted by permission from John 799 
Wiley & Sons, Inc. [Rudman, S.M. et al. Harnessing engineered antibodies of the IgE class to combat 800 
malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE 801 
antibody to evaluate the risk of type I hypersensitivity. Clin. Exp. Allergy, 2011, 41, 1400-1413 [181]]. 802 
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(d) MOv18 IgE-mediated killing of IGROV1 ovarian cancer cells by primary human eosinophils 803 
(right) and microscopic evaluations revealed interactions between IGROV1 cells and eosinophils, 804 
and IGROV1 tumour cell destruction alongside piecemeal degranulation of eosinophils, following 805 
2.5 hours incubation with MOv18 IgE, but not with non-specific NIP IgE (right) [182]. Figure adapted 806 
by permission from The American Association of Immunologists, Inc. [Karagiannis, S.N. et al. 807 
IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of 808 
eradication of ovarian cancer cells. J. Immunol. 2007, 179, 2832-2843 [182]]. 809 
The American Association of Immunologists 810 
8.2.3. In vivo efficacy studies of MOv18 IgE 811 
The ability of MOv18 IgE to restrict tumour growth in vivo was studied against different rodent 812 
models including human tumour xenografts established in immunodeficient (SCID and nu/nu) 813 
mice. In immunodeficient mouse models, human effector cell populations were co-administered 814 
with MOv18 IgE because: a) human IgE-Fc is not recognised by mouse FcεRs, and b) in mice the 815 
high-affinity IgE receptor FcεRI is expressed only by mast cells and basophils, and is absent in key 816 
effector cells such as monocytes and eosinophils. These studies therefore took place in an in vivo 817 
system containing both target and effector cells of human origin. 818 
 819 
In a s.c. human ovarian cancer (IGROV1) xenograft grown in a SCID mouse model, animals 820 
administered with mouse/human chimeric MOv18 IgE or MOv18 IgG1 intravenously (i.v.) exhibited 821 
an initial inhibition of tumour growth up to day 19 post-tumour challenge. However, the tumours in 822 
mice administered PBMCs and MOv18 IgG1 subsequently grew to the same size as controls. In 823 
contrast, mice administered PBMCs and MOv18 IgE exhibited reduced growth of up to 72% by day 824 
35 post-challenge. In a range of experiments in this model, a single treatment with MOv18 IgE and 825 
PBMC significantly restricted the growth of ovarian tumours (Figure 11a) [147]. In specimens 826 
sampled at the end of these studies, tumours from the mice that received PMBCs and MOv18 IgE 827 
showed significantly larger areas of necrosis compared with those from mice treated with 828 
non-specific control IgE plus PBMCs, or those given PBMCs alone. Furthermore, when administered 829 
to IGROV1 xenograft mice in the absence of human PBMC, MOv18 IgE did not significantly inhibit 830 
tumour growth. Therefore, in the IGROV1 xenograft model, the anti-tumour efficacy of MOv18 IgE 831 
was found to be reliant on the presence of both an effector cell population and an IgE targeted to a 832 
tumour-expressed antigen. 833 
 834 
Subsequently, a patient-derived xenograft (PDX) model of ovarian cancer was established from 835 
a human primary tumour sample, originating from the ascites of a moderately differentiated Grade 836 
3, stage III ovarian serous cystadenocarcinoma. This PDX could be passaged in nude mice while 837 
retaining its human phenotype and was found to express FRα. In efficacy studies using this model, 838 
nude mice were challenged with i.p. ascites from donor human xenograft-bearing mice and were 839 
then treated with saline, human PBMCs or PBMCs plus MOv18 IgE on days 1 and 16. The mean 840 
survival time of control mice was 22 days, for those administered PBMCs alone it was 30 days, while 841 
for those administered PBMCs plus MOv18 IgE, mean survival time was 40 days [179]. In a study 842 
comparing the efficacy of weekly doses of MOv18 IgG and IgE in this model, untreated mice 843 
survived for a median of 19 days, those administered PBMCs alone survived for 26 days, those 844 
administered PBMC plus IgG1 survived for 22 days, and those administered PBMC plus IgE 845 
survived for 40 days (Figure 11b). 846 
 847 
One limitation of studies in mouse models is the need to introduce exogenous human effector 848 
cells, thus limiting the immune functions of the model and the possible duration of study as 849 
exogenous effector cells become depleted. Therefore, an immunocompetent syngeneic tumour 850 
model in Wistar Albino Glaxo (WAG) rats was designed to study efficacy as well as safety of MOv18 851 
IgE prior to clinical translation. This model was selected based on similar expression and cellular 852 
distribution of FcεRI in rats and humans. Rat CC531 colon adenocarcinoma cells [186], engineered to  853 
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Figure 11. In vivo evaluations of MOv18 IgE. (a) In a s.c. human ovarian cancer (IGROV1) xenograft 856 
grown in a SCID mouse model, reduced tumour growth was measured in animals treated with 857 
PBMC plus MOv18 IgE, even at day 35 post tumour challenge. In comparison, animals treated with 858 
PBMC plus MOv18 IgG1 showed initial inhibition of tumour growth at day 19, but by day 35 859 
tumours grew to the same size as controls [147]. Figure adapted by permission from John Wiley & 860 
Sons, Inc. [Gould, H.J. et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and 861 
in a SCID mouse xenograft model of ovarian carcinoma. Eur. J. Immunol. 1999, 29, 3527-3537 [147]]. 862 
(b) In an orthotopically-grown (i.p.) patient-derived xenograft (PDX) model of ovarian cancer, mice 863 
treated with weekly doses of PBMC plus MOv18 IgE showed superior survival compared to 864 
untreated animals and those treated with either PBMC alone or PBMC plus MOv18 IgG [179]. Figure 865 
adapted by permission from John Wiley & Sons, Inc. [Karagiannis, S.N. et al. Activity of human 866 
monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. 867 
Immunol. 2003, 33, 1030-1040 [179]]. (c) Left panel: In an immunocompetent syngeneic tumour model 868 
in WAG rats, significantly superior tumour growth restriction was measured in animals treated 869 
fortnightly with 10 mg/kg rat MOv18 IgE compared to the rat IgG2b equivalent. Right panel: 870 
Representative images of Indian ink-stained rat lungs (left) and lung sections (right) from each 871 
treatment group are shown [185]. Figure adapted by permission from American Association for 872 
Cancer Research. [Josephs, D.H. et al. Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages 873 
to Attack Tumors via TNFα/MCP-1 Signaling. Cancer Res. 2017, 77, 1127-1141 [185]]. 874 
 875 
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express the human FRα (CC531tFR), were administered i.v. to grow as multifocal syngeneic lung 876 
metastases, and rats were administered a rat surrogate for the mouse/human chimeric MOv18 IgE 877 
engineered with rat Fc domains and respective effector functions (rat MOv18 IgE). This system 878 
permitted targeting of the rat immune system to rat tumour cells by an anti-FRα IgE. Significant 879 
efficacy of rat MOv18 IgE in restricting the growth of lung metastases was observed at doses of 880 
5 mg/kg and higher when the antibody was administered fortnightly, compared with controls [185]. 881 
The efficacy of rat MOv18 IgE and the equivalent rat IgG2b was then compared: at a 10 mg/kg 882 
fortnightly dose, rat MOv18 IgE was significantly superior at restricting tumour growth (Figure 11c). 883 
 884 
 885 
Overall, in three models of cancer including a patient-derived xenograft and an 886 
immunocompetent syngeneic model, the anti-tumour efficacy of MOv18 IgE was reliant on the 887 
presence of both an effector cell population and tumour antigen specificity. Furthermore, 888 
anti-tumour IgE was more effective than the corresponding IgG. 889 
 890 
8.3. Evidence for IgE activating monocytes and macrophages against cancer 891 
8.3.1. Monocytes and macrophages as key effector cells in MOv18 IgE-potentiated anti-tumour 892 
functions  893 
The mechanisms by which IgE antibodies can exert their anti-tumour effects have been studied and 894 
several pieces of evidence support a role for monocytes and macrophages as key effector cells.  895 
 896 
In vitro evidence for monocyte-mediated effector functions: Monocytes mediate MOv18 897 
IgE-dependent tumour cell killing in vitro by two pathways, ADCC and ADCP, acting through FcεRI 898 
and CD23 respectively. FcεRI-expressing primary monocytes principally exert ADCC. MOv18 899 
IgE-potentiated ADCC by monocytes could be blocked with recombinant sFcεRIα [180,182,187], but 900 
monocytes could kill tumour cells by ADCP, a function mediated by CD23. MOv18 IgE antibodies 901 
can thus engage both receptors to activate effector cells against tumour cells in vitro and in vivo.  902 
 903 
Evidence of macrophage involvement in IgE functions in mouse models: Pre-clinical in vivo studies in a 904 
PDX model suggested that monocytes and macrophages may be important IgE receptor-expressing 905 
effector cells that mediate enhanced survival of tumour-bearing mice treated with MOv18 IgE and 906 
human PBMCs. Treatment with MOv18 IgE was associated with histological evidence of tumour 907 
infiltration by CD68+ human monocyte-derived macrophages [180,182], suggesting that these were 908 
recruited as part of IgE-mediated anti-tumour functions. Human macrophages were concentrated in 909 
stromal areas adjacent to tumour cell islands, while mouse monocytes were abundant in all 910 
xenografts examined, irrespective of treatment. In MOv18 IgE-treated mice, human CD68+ 911 
macrophage infiltration correlated with longer survival [185]. In the same PDX model, removal of 912 
monocytes from the PBMC effector cells abolished the anti-tumour activity of co-administered 913 
PBMCs and MOv18 IgE [182]. Reconstitution of monocyte-depleted PBMCs with purified 914 
monocytes at proportions equivalent to those in unfractionated PBMCs restored the ability of 915 
PBMCs and MOv18 IgE to increase survival to levels equivalent to those seen in mice given whole 916 
PBMCs and MOv18 IgE. This survival was significantly longer than monocyte-reconstituted PBMCs 917 
alone, or depleted PBMCs with and without MOv18 IgE.  918 
 919 
In vivo evidence of IgE-mediated macrophage activation in a surrogate rat model: The mechanisms of 920 
action of rat MOv18 IgE in the WAG rat model were examined. Haematoxylin and eosin-stained 921 
tumours from different treatment groups in the WAG rat studies revealed more prominent loss of 922 
viability, density and demarcation of the tumour areas in rat MOv18 IgE-treated tumours compared 923 
to those from animals treated with rat MOv18 IgG2b or buffer alone. Rat MOv18 IgE-treated 924 
tumours demonstrated evidence of considerable necrotic tissue surrounding the smaller tumour cell 925 
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populations, consistent with previously reported tumour necrosis observed in human xenografts. 926 
Inflammatory cells infiltrating between the islands of tumour cells were considerably more 927 
pronounced in the rat MOv18 IgE-treated tumours [185]. 928 
 929 
The density and location of tumour-associated rat CD68+ macrophages in tumours from rats 930 
treated with vehicle control, rat MOv18 IgG and rat MOv18 IgE were studied by IHC and flow 931 
cytometric analyses of freshly isolated tumour-bearing lung tissues. CD68+ rat macrophages were 932 
detected in the TME from all treatment groups by IHC evaluations. Flow cytometric analyses also 933 
revealed that the percentage of CD68+ rat macrophages within the tumour-infiltrating CD45+ 934 
leukocyte population was higher in the rat MOv18 IgE-treated cohort compared to the rat MOv18 935 
IgG2b-treated or the vehicle alone-treated cohorts. Systemic rat MOv18 IgE treatment was associated 936 
with macrophage infiltration deep into the tumour islets. By contrast, macrophages were largely 937 
absent from these areas in animals administered vehicle alone, or rat MOv18 IgG. The ratio of CD68+ 938 
cells within the tumour cell islets compared wth the tumour periphery was greater in the animals 939 
administered rat MOv18 IgE than in those with rat MOv18 IgG or vehicle alone, and macrophage 940 
infiltration was inversely proportional to tumour occupancy in rats treated with antibodies. 941 
 942 
Together, these findings suggest that monocytes and macrophages may be mobilised towards 943 
tumours and play crucial roles in the tumour-restricting functions of MOv18 IgE. 944 
 945 
8.3.2. Anti-tumour IgE directs monocytes and macrophages  946 
The TME may influence the immune system to promote either anti-tumour immunity or tumour 947 
progression. Tumour associated macrophages (TAMs), characterised by the immune-activating 948 
classically-activated (M1) and the tolerance-inducing alternatively activated (M2) extreme 949 
phenotypes, are known to suppress or promote the growth of various malignant cells, depending on 950 
the biological context [188-190]. The activation state of macrophages induced to influx into tumours 951 
after administration of rat MOv18 IgE was investigated.  952 
 953 
Tumour-infiltrating macrophages from rats treated with rat MOv18 IgE demonstrated 954 
enhanced expression of the M1 co-stimulatory mature APC marker CD80, compared with those 955 
from MOv18 IgG2b or buffer-treated groups [185]. However, there was no difference in expression 956 
of the M2 marker CD163 between treatment groups. Furthermore, a considerably higher proportion 957 
of freshly-isolated CD68+ macrophages from dispersed rat lung tumours of rats administered rat 958 
MOv18 IgE were found to express intracellular TNF, an M1 macrophage marker, compared to 959 
MOv18 IgG2b and vehicle-treated tumours. In addition, a higher proportion of CD68+ macrophages 960 
from rat MOv18 IgE-treated tumours expressed intracellular IL-10, considered an M2 marker, 961 
compared with rat MOv18 IgG2b- and vehicle-treated groups, although this represented a smaller 962 
subset compared with the TNF+ population, with a proportion of cells demonstrating double 963 
positivity (TNF+/IL-10+) within the rat MOv18 IgE-treated cohort. Additional analyses showed 964 
significantly elevated circulating TNFα in IgE-treated rat sera compared with controls [191]. The 965 
tumour-infiltrating macrophages in rat MOv18 IgE-treated tumours may therefore not be typically 966 
M1 or M2, and could instead represent a unique cell subset. Cytokine profile analyses of rat lung 967 
(broncho-alveolar lavage, BAL) fluids revealed four analytes, IL-10, TNF, MCP-1 and IL-1 968 
elevated in the rat MOv18 IgE-treated compared with the rat MOv18 IgG2b-treated cohort [185]. 969 
Together with increased levels of macrophage intracellular TNF and IL-10 detected in the rat 970 
MOv18 IgE-treated rats, these data therefore indicate possible roles for TNF, MCP-1 and IL-10 in 971 
the anti-tumoural functions observed following treatment with rat MOv18 IgE. Additional 972 
transcriptomic analyses demonstrated enrichment of gene signatures associated with immune 973 
activation pathways, including those associated with IL-12 and Natural Killer (NK) cell signalling in 974 
lungs from rats treated with IgE [191]. 975 
 976 
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Taken together, these data suggest that MOv18 IgE may support TAM populations with mature 977 
phenotypes and hybrid M1/M2 features that are able to enter the tumour, trigger sustained immune 978 
activating pathways and secretion of IL-10, TNF, MCP-1 and IL-1 in tumour-bearing lungs. 979 
 980 
8.3.3. TNFα/MCP-1 axis as a mechanism of MOv18 IgE-mediated activation of human monocytes  981 
The potential of, and mechanisms by which, human IgE activates human monocytes was evaluated 982 
[185]. Consistent with in vivo findings in the rat model, tumour cell cytotoxicity potentiated by 983 
mouse/human chimeric MOv18 IgE and human PBMC effector cells was associated with 984 
significantly elevated secreted mediators MCP-1, IL-10, and TNF in co-culture supernatants, 985 
compared with either non-specific NIP IgE-treated or no antibody controls. Cross-linking of IgE, but 986 
not IgG, of different antigen specificities on the surface of human monocytes was responsible for 987 
upregulation of TNFα. Cross-linking of IgE bound to tumour cells via the Fab region did not trigger 988 
TNFα. Blocking of TNFα receptor reduced IgE-mediated tumour cell cytotoxicity. Together, these 989 
findings point to a role for TNFα on IgE-mediated anti-tumour functions. Furthermore, TNFα 990 
upregulation by monocytes could in turn promote release of the monocyte and macrophage 991 
chemoattractant MCP-1 by monocytes and a range of tumour cell types. This TNFα/MCP-1 cascade 992 
is consistent with infiltration of macrophages into tumours in at least two in vivo models of cancer, 993 
and may point to IgE-mediated mobilisation and activation of monocytes/macrophages into 994 
tumours by promoting TNFα-induced production of MCP-1 in the TME (Figure 12). 995 
 996 
Together, these findings also draw parallels with increased expression of TNFα, MCP-1 and 997 
IL-10 that are reported to be associated with IgE-dependent macrophage-mediated immune 998 
responses and clearance of parasites [123,192]. It was originally hypothesised that IgE could mount 999 
an allergic response mechanism against cancer. Nonetheless, the lack of IL-4 upregulation, a classic 1000 
allergic mediator, and the potentiation of a TNFα/MCP-1 axis observed with anti-tumour IgE 1001 
effector functions, may point to a less dominant role for an allergic, and a more prominent 1002 
IgE-driven anti-tumour mechanism normally preserved for immune defence and parasite 1003 
destruction by mobilising and activating macrophages. The implications of these findings may 1004 
include the re-direction of otherwise inert macrophage populations into tumour lesions and 1005 
activation of anti-parasitic functions of the IgE class in the Th2-biased TME against tumours [193]. 1006 
 1007 
9. Towards clinical translation of first-in-class IgE to a first-in-man clinical trial 1008 
9.1. Predicting safety of IgE: using ex vivo functional assays adapted from allergy diagnosis 1009 
In sensitized individuals, minute allergen exposure can trigger life-threatening type I systemic 1010 
hypersensitivity reactions. Despite preclinical evidence that IgE could have superior efficacy 1011 
compared with IgG, concerns remain that exogenously administered IgE could trigger a type I 1012 
hypersensitivity reaction leading to anaphylaxis. For this to occur, monoclonal IgE antibodies bound 1013 
to FcεRI on effector cells must be cross-linked by soluble multivalent allergen in the circulation 1014 
[194,195]. Potent allergens can achieve this through forming soluble multimers as discussed above, 1015 
or by aggregating into complexes cross-linked by polyclonal antibodies, likely to be IgE, specific for 1016 
these antigens [196,197].  1017 
 1018 
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Figure 12. TNFα/MCP-1 cascade as a mechanism of MOv18 IgE functions in vivo. Activation of 1021 
monocytes/macrophages by MOv18 IgE mediates a TNFα/MCP-1 axis. Cross-linking of IgE 1022 
upregulates monocyte/macrophage TNFα. TNFα in turn promotes release of the chemoattractant 1023 
MCP-1 by monocytes/macrophages and tumour cells in the TME, which could promote potent 1024 
chemotaxis of further monocytes/macrophages into tumors, resulting in enhanced tumor 1025 
cell–effector cell interactions and subsequent tumor cell death. Figure adapted by permission from 1026 
American Association for Cancer Research. [Josephs, D.H. et al. Anti-Folate Receptor-α IgE but not 1027 
IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling. Cancer Res. 2017, 77, 1028 
1127-1141 [185]]. 1029 
 1030 
In the cancer context, it is hypothesised that for an anti-tumour IgE to avoid triggering type I 1031 
hypersensitivity, the target antigen should be found at low density, and in monomeric form, on 1032 
healthy cells (and in the circulation) and/or should have only a single IgE-binding epitope, so that 1033 
IgE cross-linking on the surface of effector cells or bridging with a target cell cannot be achieved 1034 
[198]. In contrast, for an anti-tumour IgE to have anti-tumour effects, the tumour antigen should be 1035 
overexpressed on the cancer cells in tissues so that they are densely packed on the cell membrane or 1036 
in lipid rafts, so that IgE bridging may occur at tumour sites. Tumour-associated antigens such as 1037 
FRα fulfil these criteria.  1038 
  1039 
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To investigate this hypothesis, the ability of MOv18 IgE to trigger basophil degranulation was 1040 
examined using RBL SX-38 cells engineered to overexpress human FcεRI [181]. Exposure of cells to 1041 
MOv18 IgE alone did not induce significant degranulation, however cross-linking of MOv18 IgE 1042 
bound to the effector cell surface using a polyclonal anti-IgE antibody, or by cross-linking 1043 
FRα-bound IgE using an anti-FRα polyclonal antibody to mimic the effect of a circulating multimeric 1044 
antigen, induced appreciable degranulation. In contrast, when cells were incubated with MOv18 IgE 1045 
and increasing concentrations of recombinant (monovalent) FRα alone at levels up to 400-fold higher 1046 
than those reported in ovarian cancer patient blood, only background levels of degranulation were 1047 
observed. This was as expected, since monovalent antigen is generally unable to cross-link 1048 
FcRI-bound IgE [181,199]. Furthermore, while naturally-shed FRα levels in patient circulation were 1049 
significantly elevated compared with those measured from healthy controls, sera from 32 patients 1050 
with stage III or IV ovarian carcinoma, and from 14 healthy volunteers, induced only background 1051 
levels of degranulation. 1052 
 1053 
The possibility that circulating tumour cells (CTCs) or tumour cell fragments bearing multiple 1054 
copies of the target antigen could trigger degranulation was also explored by exposing RBL SX-38 1055 
effector cells to MOv18 IgE and serially increasing the number of FRα-expressing IGROV1 ovarian 1056 
carcinoma cells. Degranulation was only detected at higher E:T cell ratios, well above those recorded 1057 
in patient blood [181]. This suggests that MOv18 IgE is unlikely to activate effector cells in the 1058 
presence of even the highest reported concentration of FRα-expressing CTCs. Tumour cells that did 1059 
not express FRα did not induce degranulation, suggesting that the phenomenon is antigen-specific. 1060 
 1061 
The ability of MOv18 IgE to activate blood basophils ex vivo in fresh unfractionated blood from 1062 
patients with ovarian carcinoma was investigated using the basophil activation assay (BAT). BAT is 1063 
an increasingly useful assay conducted in unfractionated blood for detecting propensity for type I 1064 
hypersensitivity to a large range of allergens [200-203], including medicinal drugs and those used in 1065 
oncology. It is designed to measure elevated cell surface CD63 expression within 10-15 minutes of 1066 
stimulation as an early sign of type I hypersensitivity, which precedes degranulation [204]. MOv18 1067 
IgE at a range of concentrations had no effect on the level CD63 expression in whole blood samples 1068 
from healthy volunteers or from patients with ovarian carcinoma, despite detectable circulating 1069 
concentrations of FRα in the blood of some of these patients. Furthermore, MOv18 IgE with the 1070 
addition of exogenous soluble FRα, even at concentrations 10-fold higher than those observed in 1071 
patients, did not increase CD63 expression by human basophils. In contrast, cross-linking of effector 1072 
cell FcεRI using either an anti-FcεRI or anti-IgE polyclonal antibody clearly augmented CD63 1073 
expression [181]. MOv18 IgE was therefore unable to produce significant basophil activation in 1074 
human blood specimens. 1075 
 1076 
In the same study, sera from 24 patients with detectable levels of circulating FRα antigen were 1077 
also screened for the presence of anti-FRα IgG auto-antibodies. Such antibodies might potentially 1078 
cross-link the soluble FRα bound to MOv18 IgE on the surface of basophils. In 6 of 24 patient sera, 1079 
IgG auto-antibodies were detected in the range of 3-43 ng/mL. However, when tested in the RBL 1080 
SX-38 degranulation assay, sera from these patients did not trigger any functional degranulation in 1081 
the presence of MOv18 IgE. Sera from two patients were also studied in the BAT assay and induced 1082 
no increase in CD63 expression by the patients’ blood basophils [181]. 1083 
 1084 
In conclusion, no evidence of effector cell activation or degranulation could be detected in 1085 
validated models of allergy using either recombinant FRα or patient blood and sera. In addition, no 1086 
degranulation was mediated by MOv18 IgE at worst case physiological blood CTC-to-effector cell 1087 
ratios or by patient anti-FRα IgG auto-antibodies. Overall, these data indicate that when ovarian 1088 
carcinoma patients are treated with MOv18 IgE, FcεRI-mediated activation of effector cells may 1089 
potentially occur within the tumour mass but is less likely in the circulation. 1090 
 1091 
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9.2. Predicting safety of IgE: in vivo models 1092 
Selection of preclinical models to help predict the safety of IgE antibody immunotherapy of cancer is 1093 
still in its very early stages, and pharmacologically relevant species are being sought. An anti-human 1094 
HER2/neu IgE was well-tolerated when introduced to cynomolgus monkeys [160]. Cross-species 1095 
reactivity of mouse/human chimeric MOv18 IgE was demonstrated in cynomolgus monkey immune 1096 
effector cells [205]. However, the kinetics of MOv18 IgE interaction with effector cells, and the 1097 
phenotype of the activated effector cells, differed between the two species; human IgE featured a 1098 
faster dissociation from cynomolgus monkey effector cells, compared with human immune effector 1099 
cells. Human IgE triggered different cytokine release profiles by human and cynomolgus monkey 1100 
immune effector cells. Therefore, extrapolation of cynomolgus data to human may be unreliable 1101 
[205]. 1102 
 1103 
For these reasons, a surrogate syngeneic tumour model in immunocompetent (WAG) rats 1104 
(discussed above) was designed to evaluate the safety profile of anti-tumour IgE. This species was 1105 
selected because the IgE system of the rat bears many similarities to that of human, and the use of the 1106 
rat MOv18 IgE in the WAG rat would allow characterisation of IgE-mediated responses that would 1107 
not be possible in healthy primate models. 1108 
 1109 
Preclinical efficacy studies using tumour-bearing rats showed restriction of tumour growth in 1110 
the absence of any evidence of acute toxicity with rat MOv18 IgE (or with the equivalent rat MOv18 1111 
IgG2b), despite the natural presence of IgE effector cells capable of IgE-mediated degranulation such 1112 
as basophils and mast cells in this species. No evidence of cytokine storm (lack of IL-6 or IFNγ) or 1113 
signals of an allergic response (IL-4) were detected, while elevated immunological pathway 1114 
activation gene signatures, tumour and serum TNFα elevation and enhanced macrophage 1115 
infiltration into tumours, thought to be associated with anti-tumoral efficacy, were associated with 1116 
IgE treatment (Figure 13) [191]. 1117 
 1118 
In concordance, in previous immunodeficient mouse models of human FRα-expressing 1119 
carcinoma xenografts, administration of mouse/human chimeric MOv18 IgE or MOv18 IgG1 1120 
together with human peripheral blood lymphocytes and peripheral blood mononuclear cells did not 1121 
trigger any toxic effects, despite the presence of human basophils and eosinophils, including those 1122 
from allergic human donors [147,179,182], in these effector cell preparations. Further support for this 1123 
concept comes from published data demonstrating induction of IgE through tumour antigen 1124 
mimotope vaccination, detected in the absence of any toxicities or signs of type I hypersensitivity 1125 
[206]. Furthermore, IgE specific to tumour antigens and with tumoricidal properties has been 1126 
reported in patients with head and neck cancer and pancreatic cancer, in the circulation and tumour 1127 
tissues [104,105], without anaphylaxis occurring. 1128 
 1129 
Finally, dogs may be an alternative model to examine the safety and anti-tumour functions of 1130 
IgE, since this species is known for susceptibility to both cancer, including spontaneous mammary 1131 
carcinomas, and allergy, with strong similarities of FcεR expression and distribution on immune 1132 
cells compared with humans [207-209]. Efforts are underway to design canine versions of 1133 
anti-tumour IgE with a view to conduct safety and efficacy studies [152]. 1134 
  1135 
9.3. Monitoring antibody safety in trials 1136 
Translation to clinical testing is expected to entail careful monitoring of patients and measuring 1137 
functional readouts and immunological markers of type I hypersensitivity following administration 1138 
of MOv18 IgE due to the potential for basophil and/or mast cell degranulation. Functional tests may 1139 
monitor the propensity to trigger basophil activation and mast cell degranulation in patient blood 1140 
and sera ex vivo, all measured at different points of drug administration. Monitoring would include 1141 
clinical signs of type I hypersensitivity, changes in serum levels of β-tryptase, total and tumour  1142 
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 1145 
Figure 13. In vivo safety evaluations of MOv18 IgE. A surrogate syngeneic tumour model in 1146 
immunocompetent WAG rats was designed to evaluate the safety profile of MOv18 IgE. Rat CC531 1147 
colon adenocarcinoma cells, engineered to express the human FRα were administered i.v. to grow as 1148 
lung metastases and animals were treated with either rat MOv18 IgE or the IgG2b equivalent. This 1149 
model demonstrated superior efficacy of IgE compared with the IgG counterpart (representative 1150 
images of Indian ink-stained lungs shown). Efficacy was observed in the absence of any adverse 1151 
clinical observations, off-target toxicities (H&E-stained spleen shown), or haematological or 1152 
biochemical changes. Furthermore, no evidence of cytokine storm (lack of IL-6 or IFNγ upregulation) 1153 
or allergic response (lack of IL-4 upregulation) was detected. In the same model, MOv18 IgE 1154 
treatment was associated with restriction of tumour growth, alongside enhanced immune cell 1155 
infiltration in tumours (H&E-stained lung shown) and elevated immunological pathway activation 1156 
gene signatures. Additionally, increased tumour and serum TNFα were measured in association 1157 
with IgE treatment. Figure adapted by permission from John Wiley & Sons, Inc. [Josephs, D.H. et al. 1158 
An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific 1159 
IgE. Allergy 2018, 73, 2328-2341 [191]]. 1160 
 1161 
antigen-specific IgE, circulating tumour antigen and autoantibodies to the target antigen. 1162 
Specifically, serum β-tryptase elevation signifying mast cell degranulation during clinical testing 1163 
may be important to help distinguish cytokine release-type infusion reactions from type I 1164 
hypersensitivity [210,211].  1165 
 1166 
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10. Thoughts for the design of new IgE-based therapeutic agents 1167 
10.1. Expression systems and IgE glyco-profiling 1168 
Production of IgE for clinical study requires the development of GMP processes that ensure swift 1169 
production of antibody with sufficient quality, purity and stability profiles. Importantly, the product 1170 
must show physiochemical and functional profiles compatible with those of the laboratory grade 1171 
material. Additionally, IgE antibodies display seven glycosylation sites, six of which comprise 1172 
complex N-glycans, potentially with terminal galactose, fucose and sialic acid residues, as discussed 1173 
above (and illustrated for IgG in Figure 1c). Due to its heavily glycosylated structure, the 1174 
glycosylation profile of IgE antibodies must also be considered with regard to achieving a consistent 1175 
antibody structural and functional product profile for clinical application. Carbohydrates may 1176 
influence affinity for the target antigen, biodistribution, effector cell trafficking to tissues and 1177 
antibody pharmacokinetics; the high-mannonse structure at Asn394 (Figure 1d) may, as we have 1178 
discussed, have functional significance [41,50]. Monitoring the structural and functional integrity of 1179 
IgE is therefore warranted at all stages of research, development and manufacturing for pre-clinical 1180 
and clinical evaluations. Furthermore, the nature of the expression system may impact on the 1181 
glycosylation profile and must be carefully considered when designing an IgE class therapeutic 1182 
agent [153]. For instance, the carbohydrate profile of IgE antibodies produced using a human 1183 
expression system may differ from that of plant-expressed IgE [150]. Further study of glycan content 1184 
will undoubtedly provide important information for further understanding structure-function 1185 
relationships in IgE. 1186 
 1187 
10.2. Selecting tumour targets and malignant indications for IgE therapeutic agents 1188 
Rational design of suitable therapeutic agents should aim to take advantage of the tissue-resident 1189 
immune surveillance exerted by IgE antibodies that can be directed against cancer antigens, whilst 1190 
minimising the risk of potential toxic effects of the therapeutic agent. Malignant indications could be 1191 
selected according to whether tumour cells are likely to reside in tissues in which important IgE 1192 
effector cells such as macrophages are also found. Indications in which tumour cells and tumour cell 1193 
fragments do not circulate would be preferable, since following systemic administration of 1194 
anti-tumour IgE, basophils loaded with anti-tumour IgE could encounter circulating cancer cells 1195 
bearing multiple copies of the target antigen; such interactions might trigger degranulation and 1196 
potential type I hypersensitivity. Important criteria for selection of cancer antigen targets would 1197 
include high expression on the tumour with minimal and restricted distribution in normal tissues 1198 
away from patient circulation. Furthermore, selection of single epitopes on tumour antigens and 1199 
antigens that do not shed in multimeric forms in patient circulation would be key criteria for target 1200 
selection. 1201 
 1202 
10.3. Challenges for IgE-based therapies 1203 
Within the fields of Immunology, Allergy and AllergoOncology, there are many aspects of IgE 1204 
biology that are yet to be explored. The most prominent unknowns in the field are: defining the 1205 
dynamics of antibody trafficking to tumours, recruiting monocytes into tumour lesions and 1206 
engaging local tumour-associated macrophages; pharmacokinetics in patient circulation and 1207 
biodistribution in health and disease settings; the roles and anti-tumour functions of mast cells; 1208 
unexplored mechanisms of action beyond the TNFα/MCP-1 cascade; the existence of modulatory 1209 
mechanisms for IgE despite the lack of any known inhibitory FcεR; the impact of target antigen 1210 
expression levels and distribution in tumour lesions on the anti-tumour efficacy of IgE antibodies; 1211 
stratification of patients with tumours featuring immune tumour environments congruent to IgE 1212 
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antibody therapy; the most suitable administration route and malignant indication to help refine 1213 
treatment and maximise patient benefit.  1214 
 1215 
Evidence from a number of studies points to monocytes and macrophages as important effector 1216 
cells that participate in the anti-tumour functions of IgE in vitro and in vivo [193]. On the other hand, 1217 
mast cells express far higher levels of FcεRI compared with monocytes and macrophages, and 1218 
constitute another key effector cell population that may contribute to the cancer growth-restricting 1219 
functions of anti-tumour Ig£ antibodies. Mast cells can be activated upon crosslinking of FcεRI by 1220 
IgE in the presence of multivalent antigens, to degranulate and release toxic mediators in tissues 1221 
such as the skin and gut. These functions of mast cells have been known to be directed to destroy 1222 
parasites [5,97]. The significance of mast cell infiltration in tumour lesions has been controversial 1223 
[212], however there have been reports of associations with more favourable clinical outcomes [213]. 1224 
Tumour- and tissue-resident mast cells may also contribute to IgE-mediated enhanced TNFα 1225 
expression and heightened immune responses in the TME [214]. Mast cells could be recruited 1226 
towards tumour lesions either through tumour cell-produced MCP-1 [215], and more prominently 1227 
through the anti-tumour IgE-potentiated TNFα/MCP-1 axis discussed above [185,191]. However, the 1228 
roles of mast cells in the context of anti-tumour IgE mechanisms of action and efficacy require 1229 
further study.  1230 
 1231 
Further areas for investigation include the impact of clinically available therapies such as 1232 
chemotherapies, checkpoint inhibitors, steroids and targeted treatments on the following: effector 1233 
cells and IgE therapeutic efficacy and safety; expression of IgE Fc receptors by immune cells in 1234 
different cancer types and patient tumours; mechanisms by which IgE acts on the TME, including 1235 
IgE receptor-expressing and non-expressing cells, and their recruitment into tumours.  1236 
 1237 
A number of antibodies engineered with IgE Fc regions have been shown to engender potent 1238 
effector functions and restrict tumour growth in disparate model systems. These include antibodies 1239 
recognizing epitopes found on clinically-validated tumour targets such as HER2/neu. It is to be 1240 
hoped that IgE antibodies against these targets will progress along the translational pipeline 1241 
towards clinical testing. The field of AllergoOncology, including the use of IgE antibodies for cancer 1242 
treatment, will undoubtedly enrich our understanding of human immunity and responses in health 1243 
and malignant disease, and both inform and transform the design of future immunotherapeutic 1244 
agents. 1245 
 1246 
Funding: The authors acknowledge support by the Medical Research Council UK (G0501494, G1100090 and 1247 
MR/L023091/1), the Wellcome Trust (076343), Asthma UK (AUK-IG-2016-338), Breast Cancer Now (147) 1248 
working in partnership with Walk the Walk, Cancer Research UK (C30122/A11527 and C30122/A15774) and 1249 
CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre 1250 
(C10355/A15587). The research was supported by the National Institute for Health Research (NIHR) Biomedical 1251 
Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London 1252 
(IS-BRC-1215-20006). The authors are solely responsible for study design, data collection, analysis, decision to 1253 
publish, and preparation of the manuscript. The views expressed are those of the authors and not necessarily 1254 
those of the NHS, the NIHR or the Department of Health. 1255 
 1256 
Conflicts of Interest:  S.N. Karagiannis is founder and shareholder of IGEM Therapeutics Ltd. and holds a 1257 
patent on anti-tumour IgE antibodies. H.J. Bax is employed through a fund by IGEM Therapeutics Ltd. 1258 
 1259 
 1260 
 1261 
Antibodies 2018, 7, x FOR PEER REVIEW  32 of 44 
 
References 1262 
1.  Platts-Mills, T.A.; Heymann, P.W.; Commins, S.P.; Woodfolk, J.A. The discovery of IgE 50 years later. Ann. 1263 
 Allergy Asthma Immunol. 2016, 116, 179-182, doi: 10.1016/j.anai.2016.01.003. 1264 
2.  Bennich, H.H.; Ishizaka, K.; Johansson, S.G.O.; Rowe, D.S.; Stanworth, D.R.; Terry, W.D. Immunoglobulin 1265 
 E, a new class of human immunoglobulin. Bull. World Health Organ. 1968, 38, 151-152.  1266 
3. Ishizaka, K.; Ishizaka, T.; Hornbrook, M.M. Physicochemical properties of reaginic antibody. V. 1267 
 Correlation of reaginic activity with γE globulin antibody. J. Immunol. 1966, 97, 840–853. 1268 
4. Gould, H.J.; Sutton, B.J. IgE in allergy and asthma today. Nat. Rev. Immunol. 2008, 8, 205-217, doi: 1269 
 10.1038/nri2273. 1270 
5.  Mukai, K.; Tsai, M.; Starkl, P.; Marichal, T.; Galli, S.J. IgE and mast cells in host defense against parasites 1271 
 and venoms. Semin. Immunopathol. 2016, 38, 581-603, doi: 10.1007/s00281-016-0565-1. 1272 
6.  Sutton, B.J.; Davies, A.M. Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. 1273 
 Immunol. Rev. 2015, 268, 222-235, doi: 10.1111/imr.12340. 1274 
7.  Kraft, S.; Kinet, J-P. New developments in FcεRI regulation, function and inhibition. Nat. Rev. Immunol. 1275 
 2007, 7, 365-378, doi: 10.1038/nri2072. 1276 
8. Kinet, J.P. The high-affinity IgE receptor (FcRI): from physiology to pathology. Annu. Rev. Immunol. 1277 
 1999, 17, 931-972, doi: 10.1146/annurev.immunol.17.1.931. 1278 
9. Gounni, A.S.; Wellemans, V.; Yang, J.; Bellesort, F.; Kassiri, K.; Gangloff, S.; Guenounou, M.; Halayko, A.J.; 1279 
 Hamid, Q.; Lamkhioued, B. Human airway smooth muscle cells express the high affinity receptor for IgE 1280 
 (FcRI): a critical role of FcRI in human airway smooth muscle cell function. J. Immunol. 2005, 175, 1281 
 2613-2621. 1282 
10. Campbell, A.M.; Vachier, I.; Chanez, P.; Vignola, A.M.; Lebel, B.; Kochan, J.; Godard, P.; Bousquet, J. 1283 
 Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics. Am. J. Respir. 1284 
 Cell Mol. Biol. 1998, 19, 92-97, doi: 10.1165/ajrcmb.19.1.2648. 1285 
11. Untersmayr, E.; Bises, G.; Starkl, P.; Bevins, C.L.; Scheiner, O.; Boltz-Nitulescu, G.; Wrba, F.; 1286 
 Jensen-Jarolim, E. The high affinity IgE receptor FcRI is expressed by human intestinal epithelial cells. 1287 
 PLoS One 2010, 5, e9023, doi: 10.1371/journal.pone.0009023. 1288 
12. Hogarth, P.M.; Pietersz, G.A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and 1289 
 beyond. Nat. Rev. Drug Discov. 2012, 11, 311-331, doi: 10.1038/nrd2909. 1290 
13.  Conrad, D.H.; Ford, J.W.; Sturgill, J.L.; Gibb, D.R. CD23: an overlooked regulator of allergic disease. Curr. 1291 
 Allergy Asthma Rep. 2007, 7, 331-337, doi: 10.1007/s11882-007-0050-y. 1292 
14. Yukawa, K.; Kikutani, H.; Owaki, H.; Yamasaki, K.; Yokota, A.; Nakamura, H.; Barsumian, E.L.; Hardy, 1293 
 R.R.; Suemura, M.; Kishimoto, T. A B cell-specific differentiation antigen, CD23, is a receptor for IgE (Fc 1294 
 epsilon R) on lymphocytes. J. Immunol. 1987, 138, 2576-2580. 1295 
15. Bonnefoy, J.Y.; Aubry, J.P.; Peronne, C.; Wijdenes, J.; Banchereau, J. Production and characterization of a 1296 
 monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low 1297 
 affinity receptor for IgE. J. Immunol. 1987, 138, 2970-2978. 1298 
16.  Palaniyandi, S.; Tomei, E.; Li, Z.; Conrad, D.H.; Zhu, X. CD23-dependent transcytosis of IgE and immune 1299 
 complex across the polarized human respiratory epithelial cells. J. Immunol. 2011, 186, 3484-3496, doi: 1300 
 10.4049/jimmunol.1002146. 1301 
17.  Tu, Y.; Salim, S.; Bourgeois, J.; Di Leo, V.; Irvine, E.J.; Marshall, J.K.; Perdue, M.H. CD23-mediated IgE 1302 
 transport across human intestinal epithelium: inhibition by blocking sites of translation or binding. 1303 
 Gastroenterology 2005, 129, 928-940, doi: 10.1053/j.gastro.2005.06.014. 1304 
18. Li, H.; Nowak-Wegrzyn, A.; Charlop-Powers, Z.; Shreffler, W.; Chehade, M.; Thomas, S.; Roda, G.; Dahan, 1305 
 S.; Sperber, K.; Berin, M.C. Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial 1306 
 cells and its role in food allergy. Gastroenterology 2006, 131, 47-58, doi: 10.1053/j.gastro.2006.03.044. 1307 
19.  McCloskey, N.; Hunt, J.; Beavil, R.L.; Jutton, M.R.; Grundy, G.J.; Girardi, E.; Fabiane, S.M.; Fear, D.J.; 1308 
 Conrad, D.H.; Sutton, B.J.; Gould, H.J. Soluble CD23 monomers inhibit and oligomers stimulate IgE 1309 
 synthesis in human B cells. J. Biol. Chem. 2007, 282, 24083-24091, doi: 10.1074/jbc.M703195200. 1310 
20.  Gould, H.J.; Beavil, R.L.; Reljić, R.; Shi, J.; Ma, C.W.; Sutton, B.J.; Ghirlando, R. IgE Homeostasis: Is CD23 1311 
 the safety switch? In: Vercelli D, ed. IgE regulation: Molecular Mechanisms. Chichester UK: Wiley, 1997, 1312 
 37-59. 1313 
Antibodies 2018, 7, x FOR PEER REVIEW  33 of 44 
 
21.  Cooper, A.M.; Hobson, P.S.; Jutton, M.R.; Kao, M.W.; Drung, B.; Schmidt, B.; Fear, D.J.; Beavil, A.J.; 1314 
 McDonnell, J.M.; Sutton, B.J.; Gould, H.J. Soluble CD23 controls IgE synthesis and homeostasis in human 1315 
 B cells. J. Immunol. 2012, 188, 3199-3207, doi: 10.4049/jimmunol.1102689. 1316 
22.  Palaniyandi, S.; Liu, X.; Periasamy, S.; Ma, A.; Tang, J.; Jenkins, M.; Tuo, W.; Song, W.; Keegan, A.D.; 1317 
 Conrad, D.H.; Zhu, X. Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and 1318 
 development of allergic airway inflammation. Mucosal Immunol. 2015, 8, 1262-1274, doi: 1319 
 10.1038/mi.2015.16. 1320 
23. Mitropoulou, A.N.; Bowen, H.; Dodev, T.; Davies, A.M.; Bax, H.; Beavil, R.L.; Beavil, A.J.; Gould, H.J.; 1321 
 James, L.K.; Sutton, B.J. Structure of a patient-derived antibody in complex with allergen reveals 1322 
 simultaneous conventional and superantigen-like recognition. Proc. Natl. Acad. Sci. USA 2018, 115, 1323 
 E8707-E8716, doi: 10.1073/pnas.1806840115.  1324 
24.  Crispin, M.; Yu, X.; Bowden, T.A. Crystal structure of sialylated IgG Fc: Implications for the mechanism of 1325 
 intravenous immunoglobulin therapy. Proc. Natl. Acad. Sci. USA 2013, 110, E3544-E3546, doi: 1326 
 10.1073/pnas.1310657110. 1327 
25.  Doré, K.A.; Davies, A.M.; Drinkwater, N.; Beavil, A.J.; McDonnell, J.M.; Sutton, B.J. Thermal sensitivity 1328 
 and flexibility of the Cε3 domains in immunoglobulin E. Biochim. Biophys. Acta – Proteins and Proteomics 1329 
 2017, 1865, 1336-1347, doi: 10.1016/j.bbapap.2017.08.005. 1330 
26.  Zhang, X.; Calvert, R.A.; Sutton, B.J.; Doré, K.A. IgY: a key isotype in antibody evolution. Biol. Rev. Camb. 1331 
 Philos. Soc. 2017, 92, 2144-2156, doi: 10.1111/brv.12325. 1332 
27.  Feinstein, A.; Munn, E.A. Conformation of the free and antigen-bound IgM antibody molecules. Nature 1333 
 1969, 224, 1307-1309, doi: 10.1038/2241307a0. 1334 
28.  Padlan, E.A.; Davies, D.R. A model of the Fc of Immunoglobulin-E. Mol. Immunol. 1986, 23, 1063-1075. 1335 
29.  Holowka, D.; Baird, B. Structural studies on the membrane-bound immunoglobulin E (IgE)-receptor 1336 
 complex. 2. Mapping of distances between sites on IgE and the membrane surface. Biochemistry 1983, 22, 1337 
 3475-3484, doi: 10.1021/bi00283a026. 1338 
30.  Holowka, D.; Conrad, D.H.; Baird, B. Structural mapping of membrane-bound immunoglobulin-E 1339 
 receptor complexes: use of monoclonal anti-IgE antibodies to probe the conformation of receptor-bound 1340 
 IgE.  Biochemistry 1985, 24, 6260–6267, doi: 10.1021/bi00343a033. 1341 
31.  Zheng, Y.; Shopes, B.; Holowka, D.; Baird, B. Conformations of IgE bound to its receptor FcεRI and in 1342 
 solution. Biochemistry 1991, 30, 9125-9132, doi: 10.1021/bi00102a002. 1343 
32.  Zheng, Y.; Shopes, B.; Holowka, D.; Baird, B. Dynamic conformations compared for IgE and IgG1 in 1344 
 solution and bound to receptors. Biochemistry 1992, 31, 7446-7456, doi: 10.1021/bi00148a004. 1345 
33.  Beavil, A.J.; Young, R.J.; Sutton, B.J.; Perkins, S.J. Bent domain structure of recombinant human IgE-Fc in 1346 
 solution by X-ray and neutron scattering in conjunction with an automated curve fitting procedure. 1347 
 Biochemistry 1995, 34, 14449-14461, doi: 10.1021/bi00044a023. 1348 
34. Wan, T.; Beavil, R.L.; Fabiane, S.M.; Beavil, A.J.; Sohi, M.K.; Keown, M.; Young, R.J.; Henry, A.J.; 1349 
 Owens, R.J.; Gould, H.J.; Sutton, B.J. The crystal structure of IgE Fc reveals an asymmetrically bent 1350 
 conformation. Nat. Immunol. 2002, 3, 681-686, doi: 10.1038/ni811.   1351 
35. Davies, A.M.; Allan, E.G.; Keeble, A.H.; Delgado, J.; Cossins, B.P.; Mitropoulou, A.N.; Pang, M.O.Y.; 1352 
 Ceska, T.; Beavil, A.J.; Craggs, G.; Westwood, M.; Henry, A.J.; McDonnell, J.M.; Sutton, B.J. Allosteric 1353 
 mechanism of action of the therapeutic anti-IgE antibody  omalizumab. J. Biol. Chem. 2017, 292, 9975-9987, 1354 
 doi: 10.1074/jbc.M117.776476.  1355 
36. Drinkwater, N.; Cossins, B.P.; Keeble, A.H.; Wright, M.; Cain, K.; Hailu, H.; Oxbrow, A.; Delgado, J.; 1356 
 Shuttleworth, L.K.; Kao, M.W.; McDonnell, J.M.; Beavil, A.J.; Henry, A.J.; Sutton, B.J. Human 1357 
 immunoglobulin E flexes between acutely bent and extended conformations. Nat. Struct. Mol. Biol. 2014, 1358 
 21, 397-404, doi: 10.1038/nsmb.2795.  1359 
37. Chen, J-B.; Ramadani, F.; Pang, M.O.Y.; Beavil, R.L.; Holdom, M.D.; Mitropoulou, A.N.; Beavil, A.J.; 1360 
 Gould, H.J.; Chang, T-W.; Sutton, B.J.; McDonnell, J.M.; Davies, A.M. Structural basis for selective 1361 
 inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody. Sci. Rep. 2018, 8, 11548, 1362 
 doi: 10.1038/s41598-018-29664-4. 1363 
38. Hunt, J.; Keeble, A.H.; Dale, R.E.; Corbett, M.K.; Beavil, R.L.; Levitt, J.; Swann, M.J.; Suhling, K.; 1364 
 Ameer-Beg, S.; Sutton, B.J.; Beavil, A.J. A fluorescent biosensor reveals conformational changes in human 1365 
 immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen 1366 
 recognition. J. Biol. Chem. 2012, 287, 17459-17470, doi: 10.1074/jbc.M111.331967. 1367 
Antibodies 2018, 7, x FOR PEER REVIEW  34 of 44 
 
39. Arnold, J.N.; Radcliffe, C.M.; Wormald, M.R.; Royle, L.; Harvey, D.J.; Crispin, M.; Dwek, R.A.; Sim, R.B.; 1368 
 Rudd, P.M. The glycosylation of human serum IgD and IgE and the accessibility of identified 1369 
 oligomannose structures for interaction with mannan-binding lectin. J. Immunol. 2004, 173, 6831-6840, 1370 
 doi: 10.4049/jimmunol.173.11.6831. 1371 
40. Plomp, R.; Hensbergen, P.J.; Rombouts, Y.; Zauner, G.; Dragan, I.; Koeleman, C.A.; Deelder, A.M.; Wuhrer, 1372 
 M. Site-specific N-glycosylation analysis of human immunoglobulin E. J. Proteome Res. 2014, 13, 536-546, 1373 
 doi: 10.1021/pr400714w. 1374 
41. Shade, K.T.; Platzer, B.; Washburn, N.; Mani, V.; Bartsch, Y.C.; Conroy, M.; Pagan, J.D.; Bosques, C.; 1375 
 Mempel, T.R.; Fiebiger, E.; Anthony, R.M. A single glycan on IgE is indispensible for initiation of 1376 
 anaphylaxis. J. Exp. Med. 2015, 212, 457-467, doi: 10.1084/jem.20142182.  1377 
42.  Fridriksson, E.K.; Beavil, A.; Holowka, D.; Gould, H.J.; Baird, B.; McLafferty, F.W. Heterogeneous 1378 
 glycosylation of immunoglobulin E constructs characterized by top-down high-resolution 2-D mass 1379 
 spectrometry. Biochemistry 2000, 39, 3369-3376, doi: 10.1021/bi9919091. 1380 
43.  Taylor, A.I.; Fabiane, S.M.; Sutton, B.J.; Calvert, R.A. The crystal structure of an avian IgY-Fc fragment 1381 
 reveals conservation with both mammalian IgG and IgE. Biochemistry 2009, 48, 558-562, doi: 1382 
 10.1021/bi8019993. 1383 
44. Holdom, M.D.; Davies, A.M.; Nettleship, J.E.; Bagby, S.C.; Dhaliwal, B.; Girardi, E.; Hunt, J.; Gould, H.J.; 1384 
 Beavil, A.J.; McDonnell, J.M.; Owens, R.J.; Sutton, B.J. Conformational changes in IgE contribute to its 1385 
 uniquely slow dissociation rate from receptor FcεRI. Nat. Struct. Mol. Biol. 2011, 18, 571-576, doi: 1386 
 10.1038/nsmb.2044.   1387 
45.  Arnold, J.N.; Wormald, M.R.; Sim, R.B.; Rudd, P.M.; Dwek, R.A. The impact of glycosylation on the 1388 
 biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25, 21-50, doi: 1389 
 10.1146/annurev.immunol.25.022106.141702. 1390 
46. Helm, B.; Marsh, P.; Vercelli, D.; Padlan, E.; Gould, H.; Geha, R. The mast cell binding site on human 1391 
 immunoglobulin E. Nature 1988, 331, 180-183, doi: 10.1038/331180a0. 1392 
47. Vercelli, D.; Helm, B.; Marsh, P.; Padlan, E.; Geha, R.; Gould, H. The B-cell binding site on human 1393 
 immunoglobulin E. Nature 1989, 338, 649-651, doi: 10.1038/338649a0.  1394 
48. Basu, M.; Hakimi, J.; Dharm, E.; Kondas, J.A.; Tsien, W.H.; Pilson, R.S.; Lin, P.; Gilfillan, A.; Haring, P.; 1395 
 Braswell, E.H.; Nettleton, M.Y.; Kochan, J.P. Purification and characterization of human recombinant 1396 
 IgE-Fc fragments that bind to the human high affinity IgE receptor. J. Biol. Chem. 1993, 268, 13118-13127. 1397 
49. Hunt, J.; Beavil, R.L.; Calvert, R.A.; Gould, H.J.; Sutton, B.J.; Beavil, A.J. Disulfide linkage controls the 1398 
 affinity and stoichiometry of IgE Fc3-4 binding to FcRI. J. Biol. Chem. 2005, 280, 16808-16814, doi: 1399 
 10.1074/jbc.M500965200. 1400 
50.  Sayers, I.; Cain, S.A.; Swan, J.R.; Pickett, M.A.; Watt, P.J.; Holgate, S.T.; Padlan, E.A.; Schuck, P.; Helm, B.A. 1401 
 Amino acid residues that influence FcRI-mediated effector functions of human immunoglobulin E. 1402 
 Biochemistry 1998, 37, 16152-16164, doi: 10.1021/bi981456k. 1403 
51. Dhaliwal, B.; Yuan, D.; Pang, M.O.; Henry, A.J.; Cain, K.; Oxbrow, A.; Fabiane, S.M.; Beavil, A.J.; 1404 
 McDonnell, J.M.; Gould, H.J.; Sutton, B.J. Crystal structure of IgE bound to its B-cell receptor CD23 1405 
 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proc. Natl. Acad. 1406 
 Sci. USA 2012, 109, 12686-12691, doi: 10.1073/pnas.1207278109. 1407 
52.  Cohen, E.S.; Dobson, C.L.; Käck, H.; Wang, B.; Sims, D.A.; Lloyd, C.O.; England, E.; Rees, D.G.; Guo, H.; 1408 
 Karagiannis, S.N.; O'Brien, S.; Persdotter, S.; Ekdahl, H.; Butler, R.; Keyes, F.; Oakley, S.; Carlsson, M.; 1409 
 Briend, E.; Wilkinson, T.; Anderson, I.K.; Monk, P.D.; von Wachenfeldt, K.; Eriksson, P.O.; Gould, H.J.; 1410 
 Vaughan, T.J.; May,  R.D. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled 1411 
 asthma. mAbs 2014, 6, 755-763, doi: 10.4161/mabs.28394.  1412 
53. Dhaliwal, B.; Pang, M.O.; Keeble, A.H.; James, L.K.; Gould, H.J.; McDonnell, J.M.; Sutton, B.J.; Beavil, A.J. 1413 
 IgE binds asymmetrically to its B cell receptor CD23. Sci. Rep. 2017, 7, 45533, doi: 10.1038/srep45533. 1414 
54. Yuan, D.; Keeble, A.H.; Hibbert, R.G.; Fabiane, S.; Gould, H.J.; McDonnell, J.M.; Beavil, A.J.; Sutton, B.J.; 1415 
 Dhaliwal, B. Ca2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human 1416 
 immunoglobulin E. J. Biol. Chem. 2013, 288, 21667-21677, doi: 10.1074/jbc.M113.480657. 1417 
55.  Dhaliwal, B.; Pang, M.O.Y.; Yuan, D.; Beavil, A.J.; Sutton, B.J. A range of Cε3-Cε4 interdomain angles in 1418 
 IgE Fc accommodate binding to its receptor CD23. Acta Crystallogr. F Struct. Biol. Commun. 2014, 70, 1419 
 305-309, doi: 10.1107/S2053230X14003355.  1420 
Antibodies 2018, 7, x FOR PEER REVIEW  35 of 44 
 
56.  Garman, S.C.; Wurzburg, B.A.; Tarchevskaya, S.S.; Kinet, J-P.; Jardetzky, T.S. Structure of the Fc fragment 1421 
 of human IgE bound to its high-affinity receptor FcεRIα. Nature 2000, 406, 259-266, doi: 10.1038/35018500.  1422 
57. Wurzburg, B.A.; Garman, S.C.; Jardetzky, T.S. Structure of the human IgE-Fc Cε3-Cε4 reveals 1423 
 conformational flexibility in the antibody effector domains. Immunity 2000, 13, 375-385, doi: 1424 
 10.1016/S1074-7613(00)00037-6. 1425 
58.  Wurzburg, B.A.; Jardetzky, T.S. Conformational Flexibility in the IgE-Fc3-4 Revealed in Multiple Crystal 1426 
 Forms. J. Mol. Biol. 2009, 393, 176-190, doi: 10.1016/j.jmb.2009.08.012. 1427 
59.  Jabs, F.; Plum, M.; Laursen, N.S.; Jensen, R.K.; Mølgaard, B.; Miehe, M.; Mandolesi, M.; Rauber, M.M.; 1428 
 Pfützner, W.; Jakob, T.; Möbs, C.; Andersen, G.R.; Spillner, E. Trapping IgE in a closed conformation by 1429 
 mimicking CD23 binding prevents and disrupts FcεRI interaction. Nat. Commun. 2018, 9, 7, doi: 1430 
 10.1038/s41467-017-02312-7. 1431 
60.  Oi, V.T.; Vuong, T.M.; Hardy, R.; Reidler, J.; Dangl, J.; Herzenberg, L.A.; Stryer, L. Correlation between 1432 
 segmental flexibility and effector function of antibodies. Nature 1983, 307, 136-140, doi: 10.1038/307136a0. 1433 
61. Gould, H.J.; Sutton, B.J.; Beavil, A.J.; Beavil, R.L.; McCloskey, N.; Coker, H.A.; Fear, D.; Smurthwaite, L. 1434 
 The biology of IgE and the basis of allergic disease. Annu. Rev. Immunol. 2003, 21, 579-628, doi: 1435 
 10.1146/annurev.immunol.21.120601.141103. 1436 
62. Hibbert, R.G.; Teriete, P.; Grundy, G.J.; Beavil, R.L.; Reljic, R.; Holers, V.M.; Hannan, J.P.; Sutton, B.J.; 1437 
 Gould, H.J.; McDonnell, J.M. The structure of human CD23 and its interactions with IgE and CD21. J. Exp. 1438 
 Med. 2005, 202, 751-760, doi: 10.1084/jem.20050811. 1439 
63. Aubry, J-P.; Pochon, S.; Graber, P.; Jansen, K.U.; Bonnefoy, J-Y. CD21 is a ligand for CD23 and regulates 1440 
 IgE production. Nature 1992, 358, 505-507, doi: 10.1038/358505a0. 1441 
64. Richards, M.L.; Katz, D.H. The binding of IgE to murine FcRII is calcium-dependent but not inhibited by 1442 
 carbohydrate. J. Immunol. 1990, 144, 2638-2646. 1443 
65. Karagiannis, S.N.; Warrack, J.K.; Jennings, K.H.; Murdock, P.R.; Christie, G.; Moulder, K.; Sutton, B.J.; 1444 
 Gould, H.J. Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. 1445 
 Immunology 2001, 103, 319-331, doi: 10.1046/j.1365-2567.2001.01238.x. 1446 
66. Andersen, C.B.F.; Moestrup, S.K. How calcium makes endocytic receptors attractive. Trends Biochem. Sci. 1447 
 2014, 39, 82-90, doi: 10.1016/j.tibs.2013.12.003. 1448 
67.  Kelly, A.E.; Chen, B-H.; Woodward, E.C.; Conrad, D.H. Production of a chimeric form of CD23 that is 1449 
 oligomeric and blocks IgE binding to the FcεRI. J. Immunol. 1998, 161, 6696-6704. 1450 
68.  Suemura, M.; Kikutani, H.; Sugiyama, K.; Uchibayashi, N.; Aitani, M.; Kuritani, T.; Barsumian, E.L.; 1451 
 Yamatodani, A.; Kishimoto, T. Significance of soluble Fcε receptor II (sFcεRII/CD23) in serum and possible 1452 
 application of sFcεRII for the prevention of allergic reactions. Allergy Proc. 1991, 12, 133-137.  1453 
69.  Borthakur, S.; Hibbert, R.G.; Pang, M.O.; Yahya, N.; Bax, H.J.; Kao, M.W.; Cooper, A.M.; Beavil, A.J.; 1454 
 Sutton, B.J.; Gould, H.J.; McDonnell, J.M. Mapping of the CD23 binding site on immunoglobulin E (IgE) 1455 
 and  allosteric control of the IgE-FcεRI interaction. J. Biol. Chem. 2012, 287, 31457-31461, doi: 1456 
 10.1074/jbc.C112.397059. 1457 
70. Henry, A.J.; McDonnell, J.M.; Ghirlando, R.; Sutton, B.J.; Gould, H.J. Conformation of the isolated C3 1458 
 domain of IgE and its complex with the high-affinity receptor, FcRI. Biochemistry 2000, 39, 7406-7413, 1459 
 doi: 10.1021/bi9928391. 1460 
71. Vangelista, L.; Laffer, S.; Turek, R.; Grönlund, H.; Sperr, W.R.; Valent, P.; Pastore, A.; Valenta, R. The 1461 
 immunoglobulin-like modules C3 and 2 are the minimal units necessary for human IgE-FRI 1462 
 interaction. J. Clin. Invest. 1999, 103, 1571-1578, doi: 10.1172/JCI6551.  1463 
72. Price, N.E.; Price, N.C.; Kelly, S.M.; McDonnell, J.M. The key role of protein flexibility in modulating IgE 1464 
 interactions. J. Biol. Chem. 2005, 280, 2324-2330, doi: 10.1074/jbc.M409458200. 1465 
73. Harwood, N.E.; McDonnell, J.M. The intrinsic flexibility of IgE and its role in binding FcRI. Biomed. 1466 
 Pharmacother. 2007, 61, 61-67, doi: 10.1016/j.biopha.2006.11.004. 1467 
74. Borthakur, S.; Andrejeva, G.; McDonnell, J.M. Basis of the intrinsic flexibility of the C3 domain of IgE. 1468 
 Biochemistry 2011, 50, 4608-4614, doi: 10.1021/bi200019y. 1469 
75. Dhaliwal, B.; Pang, M.O.; Yuan, D.; Yahya, N.; Fabiane, S.M.; McDonnell, J.M.; Gould, H.J.; Beavil, A.J.; 1470 
 Sutton, B.J. Conformational plasticity at the IgE-binding site of the B-cell receptor CD23. Mol. Immunol. 1471 
 2013, 56, 693-697, doi: 10.1016/j.molimm.2013.07.005. 1472 
76. Dorrington, K.J.; Bennich, H. Thermally induced structural changes in immunoglobulin E. J. Biol. Chem. 1473 
 1973, 248, 8378-8384. 1474 
Antibodies 2018, 7, x FOR PEER REVIEW  36 of 44 
 
77.  Eggel, A.; Baravalle, G.; Hobi, G.; Kim, B.; Buschor, P.; Forrer, P.; Shin, J.S.; Vogel, M.; Stadler, B.M.; 1475 
 Dahinden, C.A.; Jardetzky, T.S. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors 1476 
 actively desensitizes allergic effector cells. J. Allergy Clin. Immunol. 2014, 133, 1709-171, doi: 1477 
 10.1016/j.jaci.2014.02.005.  1478 
78. Pennington, L.F.; Tarchevskaya, S.; Brigger, D.; Sathiyamoorthy, K.; Graham, M.T.; Nadeau, K.C.; Eggel, 1479 
 A.; Jardetzky, T.S. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat. 1480 
 Commun. 2016, 7, 11610, doi: 10.1038/ncomms11610. 1481 
79.  Kim, B.; Eggel, A.; Tarchevskaya, S.S.; Vogel, M.; Prinz, H.; Jardetzky, T.S. Accelerated disassembly of 1482 
 IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 2012, 491, 613-617, doi: 1483 
 10.1038/nature11546. 1484 
80.  Roux, K.H.; Strelets, L.; Brekke, O.H.; Sandlie, I.; Michaelsen, T.E. Comparisons of the ability of human 1485 
 IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and 1486 
 geometry. J. Immunol. 1998, 161, 4083-4090. 1487 
81.  Gieras, A.; Linhart, B.; Roux, K.H.; Dutta, M.; Khodoun, M.; Zafred, D.; Cabauatan, C.R.; Lupinek, C.; 1488 
 Weber, M.; Focke-Tejkl, M.; Keller, W.; Finkelman, F.D.; Valenta, R. IgE epitope proximity determines 1489 
 immune complex shape and effector cell activation capacity. J. Allergy Clin. Immunol. 2016, 137, 1490 
 1557-1565, doi: 10.1016/j.jaci.2015.08.055. 1491 
82.  Christensen, L.H.; Holm, J.; Lund, G.; Riise, E.; Lund, K. Several distinct properties of the IgE repertoire 1492 
 determine effector cell degranulation in response to allergen challenge. J. Allergy Clin. Immunol. 2008, 122, 1493 
 298-304, doi: 10.1016/j.jaci.2008.05.026. 1494 
83. Padlan, E.A.; Silverton, E.W.; Sheriff, S.; Cohen, G.H.; Smith-Gill. S.J.; Davies, D.R. Structure of an 1495 
 antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc. Natl. Acad. Sci 1496 
 USA 1989, 86, 5938-5942, doi: 10.1073/pnas.86.15.5938. 1497 
84. Mirza, O.; Henriksen, A.; Ipsen, H.; Larsen, J.N.; Wissenbach, M.; Spangfort, M.D.; Gajhede, M. Dominant 1498 
epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine 1499 
IgG antibody and the major allergen from birch pollen Bet v 1. J. Immunol. 2000, 165, 331-338, doi: 1500 
10.4049/jimmunol.165.1.331. 1501 
85. Padavattan, S.; Schirmer, T.; Schmidt, M.; Akdis, C.; Valenta, R.; Mittermann, I.; Soldatova, L.; Slater, J.; 1502 
Mueller, U.; Markovic-Housley, Z. Identification of a B-cell Epitope of Hyaluronidase, a Major Bee Venom 1503 
Allergen, from its Crystal Structure in Complex with a Specific Fab. J. Mol. Biol. 2007, 368, 742-752, doi: 1504 
10.1016/j.jmb.2007.02.036. 1505 
86. Li, M.; Gustchina, A.; Alexandratos, J.; Wlodawer, A.; Wünschmann, S.; Kepley, C.L.; Chapman, M.D.; 1506 
 Pomés, A. Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal 1507 
 antibody. J. Biol. Chem. 2008, 283, 22806-22814, doi: 10.1074/jbc.M800937200. 1508 
87.  Chruszcz, M.; Pomés, A.; Glesner, J.; Vailes, L.D.; Osinski, T.; Porebski, P.J.; Majorek, K.A.; Heymann, 1509 
P.W.; Platts-Mills, T.A.; Minor, W.; Chapman, M.D. Molecular determinants for antibody binding on 1510 
group 1 house dust mite allergens. J. Biol. Chem. 2012, 287, 7388-7398, doi: 10.1074/jbc.M111.311159. 1511 
88. Li, M.; Gustchina, A.; Glesner, J.; Wünschmann, S.; Vailes, L.D.; Chapman, M.D.; Pomés, A.; Wlodawer, A. 1512 
Carbohydrates Contribute to the Interactions between Cockroach Allergen Bla g 2 and a Monoclonal 1513 
Antibody. J. Immunol. 2011, 186, 333-340, doi: 10.4049/jimmunol.1002318. 1514 
89. Osinski, O.; Pomés, A.; Majorek, K.A.; Glesner, J.; Offermann, L.R.; Vailes, L.D.; Chapman, M.D.; Minor, 1515 
 W.; Chruszcz, M. Structural Analysis of Der p 1–Antibody Complexes and Comparison with Complexes of 1516 
 Proteins or Peptides with Monoclonal Antibodies. J. Immunol. 2015, 195, 307-316, doi: 1517 
 10.4049/jimmunol.1402199. 1518 
90.  Orengo, J.M.; Radin, A.R.; Kamat, V.; Badithe, A.; Ben, L.H.; Bennett, B.L.; Zhong, S.; Birchard, D.; 1519 
 Limnander, A.; Rafique, A.; Bautista, J.; Kostic, A.; Newell, D.; Duan, X.; Franklin, M.C.; Olson, W.; Huang, 1520 
 T.; Gandhi, N.A.; Lipsich, L.; Stahl, N.; Papadopoulos, N.J.; Murphy, A.J.; Yancopoulos, G.D. Treating cat 1521 
 allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat. Commun. 1522 
 2018, 9, 1421, doi: 10.1038/s41467-018-03636-8. 1523 
91.  Niemi, M.; Jylhä, S.; Laukkanen, M-L.; Söderlund, H.; Mäkinen-Kiljunen, S.; Kallio, J.M.; Hakulinen, N.; 1524 
 Haahtela, T.; Takkinen, K.; Rouvinen, J. Molecular Interactions between a Recombinant IgE Antibody and 1525 
 the β-Lactoglobulin Allergen. Structure 2007, 15, 1413-1421, doi: 10.1016/j.str.2007.09.012.  1526 
92.  Padavattan, S.; Flicker, S.; Schirmer, T.; Madritsch, C.; Randow, S.; Reese, G.; Vieths, S.; Lupinek, C.; Ebner, 1527 
 C.; Valenta, R.; Markovic-Housley, Z. High-affinity IgE recognition of a conformational epitope of the 1528 
Antibodies 2018, 7, x FOR PEER REVIEW  37 of 44 
 
 major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J. Immunol. 2009, 182, 2141-2151, 1529 
 doi: 10.4049/jimmunol.0803018. 1530 
93.  Glesner, J.; Wünschmann, S.; Li, M.; Gustchina, A.; Wlodawer, A.; Himly, M.; Chapman, M.D.; Pomés, A. 1531 
 Mechanisms of allergen-antibody interaction of cockroach allergen Bla g 2 with monoclonal antibodies 1532 
 that inhibit IgE antibody binding. PLoS One 2011, 6, e22223, doi: 10.1371/journal.pone.0022223. 1533 
94.  Marone, G.; Rossi, F.W.; Detoraki, A.; Granata, F.; Marone, G.; Genovese, A.; Spadaro, G. Role of 1534 
 superallergens in allergic disorders. Chem. Immunol. Allergy 2007, 93, 195-213, doi: 10.1159/000100896. 1535 
95. Zacharia, B.E.; Sherman, P. Atopy, helminths, and cancer. Med. Hypotheses. 2003, 60, 1-5, doi: 1536 
 10.1016/S0306-9877(02)00217-7. 1537 
96.  Finkelman, F.D.; Urban, J.F. Jr. The other side of the coin: the protective role of the TH2 cytokines. J. 1538 
 Allergy Clin. Immunol. 2001, 107, 772-780, doi: 10.1067/mai.2001.114989. 1539 
97.  Gurish, M.F.; Bryce, P.J.; Tao, H.; Kisselgof, A.B.; Thornton, E.M.; Miller, H.R.; Friend, D.S.; Oettgen, H.C. 1540 
 IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella 1541 
 spiralis. J. Immunol. 2004, 172, 1139-1145, doi: 10.4049/jimmunol.172.2.1139. 1542 
98. Ure, D.M. Negative association between allergy and cancer. Scott. Med. J. 1969, 14, 51-54,  doi: 1543 
 10.1177/003693306901400203. 1544 
99.  Schlitter, H.E. [Is there an allergy against malignant tumor tissue and what can it signify in regard to the 1545 
 defense of the body against cancer?]. Strahlentherapie, 1961, 114, 203-204. 1546 
100.  McCormick, D.P.; Ammann, A.J.; Ishizaka, K.; Miller, D.G.; Hong, R. A study of allergy in patients with 1547 
 malignant lymphoma and chronic lymphocytic leukemia. Cancer 1971, 27, 93-99, doi: 1548 
 10.1002/1097-0142(197101)27:1<93::AID-CNCR2820270114>3.0.CO;2-0. 1549 
101.  Augustin, R.; Chandradasa, K.D. IgE levels and allergic skin reactions in cancer and non-cancer patients. 1550 
 Int. Arch. Allergy Appl. Immunol. 1971, 41, 141-143, doi: 10.1159/000230505. 1551 
102.  Jacobs, D.; Landon, J.; Houri, M.; Merrett, T.G. Circulating levels of immunoglobulin E in patients with 1552 
 cancer. Lancet 1972, 2, 1059-1061, doi: 10.1016/S0140-6736(72)92341-0. 1553 
103.  Allegra, J.; Lipton, A.; Harvey, H.; Luderer, J.; Brenner, D.; Mortel, R.; Demers, L.; Gillin, M.; White, D.; 1554 
 Trautlein, J. Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer 1555 
 Res. 1976, 36, 3225-3226. 1556 
104.  Neuchrist, C.; Kornfehl, J.; Grasl, M.; Lassmann, H.; Kraft, D.; Ehrenberger, K.; Scheiner, O. Distribution of 1557 
 immunoglobulins in squamous cell carcinoma of the head and neck. Int. Arch. Allergy Immunol. 1994, 104, 1558 
 97-100, doi: 10.1159/000236714. 1559 
105.  Fu, S.L.; Pierre, J.; Smith-Norowitz, T.A.; Hagler, M.; Bowne, W.; Pincus, M.R.; Mueller, C.M.; Zenilman, 1560 
 M.E.; Bluth, M.H. Immunoglobulin E antibodies from pancreatic cancer patients mediate 1561 
 antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin. Exp. Immunol. 2008, 1562 
 153, 401-409, doi: 10.1111/j.1365-2249.2008.03726.x. 1563 
106.  Crawford, G.; Hayes, M.D.; Seoane, R.C.; Ward, S.; Dalessandri, T.; Lai, C.; Healy, E.; Kipling, D.; Proby, 1564 
 C.; Moyes, C.; Green, K.; Best, K.; Haniffa, M.; Botto, M.; Dunn-Walters, D.; Strid, J. Epithelial damage and 1565 
 tissue γδ T cells promote a unique tumor-protective IgE response. Nat. Immunol. 2018, 19, 859-870, doi: 1566 
 10.1038/s41590-018-0161-8. 1567 
107.  Disney-Hogg, L.; Cornish, A.J.; Sud, A.; Law, P.J.; Kinnersley, B.; Jacobs, D.I.; Ostrom, Q.T.; Labreche, K.; 1568 
 Eckel-Passow, J.E.; Armstrong, G.N.; Claus, E.B.; Il'yasova, D.; Schildkraut, J.; Barnholtz-Sloan, J.S.; Olson, 1569 
 S.H.; Bernstein, J.L.; Lai, R.K.; Schoemaker, M.J.; Simon, M.; Hoffmann, P.; Nöthen, M.M.; Jöckel, K.H.; 1570 
 Chanock, S.; Rajaraman, P.; Johansen, C.; Jenkins, R.B.; Melin, B.S.; Wrensch, M.R.; Sanson, M.; Bondy, 1571 
 M.L.; Houlston, R.S. Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Med. 2018, 1572 
 16, 42, doi: 10.1186/s12916-018-1027-5. 1573 
108.  Helby, J.; Bojesen, S.E.; Nielsen, S.F.; Nordestgaard, B.G. IgE and risk of cancer in 37 747 individuals 1574 
 from the general population. Ann. Oncol. 2015, 26, 1784-1790, doi: 10.1093/annonc/mdv231. 1575 
109. Liao, H.C.; Wu, S.Y.; Ou, C.Y.; Hsiao, J.R.; Huang, J.S.; Tsai, S.T.; Huang, C.C.; Wong, T.Y.; Lee, W.T.; 1576 
 Chen, K.C.; Fang, S.Y.; Wu, J.L.; Huang, T.T.; Wu, Y.H.; Hsueh, W.T.; Yen, C.J.; Yang, M.W.; Lin, F.C.; Lai, 1577 
 Y.H.; Chang, J.Y.; Lin, C.L.; Wang, Y.H.; Weng, Y.L.; Yang, H.C.; Chen, Y.S.; Chang, J.S. Allergy symptoms, 1578 
 serum total immunoglobulin E, and risk of head and neck cancer. Cancer Causes Control 2016, 27, 1105-1115, 1579 
 doi: 10.1007/s10552-016-0788-4. 1580 
110. Wulaningsih, W.; Holmberg, L.; Garmo, H.; Karagiannis, S.N.; Ahlstedt, S.; Malmstrom, H.; Lambe, M.; 1581 
 Hammar, N.; Walldius, G.; Jungner, I.; Ng, T.; Van Hemelrijck, M. Investigating the association between 1582 
Antibodies 2018, 7, x FOR PEER REVIEW  38 of 44 
 
 allergen-specific immunoglobulin E, cancer risk and survival. Oncoimmunology 2016, 5, e1154250, doi: 1583 
 10.1080/2162402X.2016.1154250. 1584 
111. Taghizadeh, N.; Vonk, J.M.; Hospers, J.J.; Postma, D.S.; de Vries, E.G.; Schouten, J.P.; Boezen, H.M. 1585 
 Objective allergy markers and risk of cancer mortality and hospitalization in a large population-based 1586 
 cohort. Cancer Causes Control 2015, 26, 99-109, doi: 10.1007/s10552-014-0489-9. 1587 
112. Van Hemelrijck, M.; Karagiannis, S.N.; Rohrmann, S. Atopy and prostate cancer: Is there a link between 1588 
 circulating levels of IgE and PSA in humans? Cancer Immunol. Immunother. 2017, 66, 1557-1562, doi: 1589 
 10.1007/s00262-017-2048-1. 1590 
113. Kural, Y.B.; Su, O.; Onsun, N.; Uras, A.R. Atopy, IgE and eosinophilic cationic protein concentration, 1591 
 specific IgE positivity, eosinophil count in cutaneous T Cell lymphoma. Int. J. Dermatol. 2010, 49, 390-395, 1592 
 doi: 10.1111/j.1365-4632.2010.04228.x. 1593 
114. Kretschmer, A.; Schwanbeck, R.; Valerius, T.; Rösner, T. Antibody Isotypes for Tumor Immunotherapy. 1594 
 Transfus. Med. Hemother. 2017, 44, 320-326, doi: 10.1159/000479240. 1595 
115. Leusen, J.H. IgA as therapeutic antibody. Mol. Immunol. 2015, 68, 35-39, doi: 1596 
 10.1016/j.molimm.2015.09.005. 1597 
116. Lohse, S.; Meyer, S.; Meulenbroek, L.A.; Jansen, J.H.; Nederend, M.; Kretschmer, A.; Klausz, K.; 1598 
 Möginger, U.; Derer, S.; Rösner, T.; Kellner, C.; Schewe, D.; Sondermann, P.; Tiwari, S.; Kolarich, D.; Peipp, 1599 
 M.; Leusen, J.H.; Valerius, T. An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid 1600 
 Effector Cell Engagement In Vivo. Cancer Res. 2016, 76, 403-417, doi: 10.1158/0008-5472.CAN-15-1232. 1601 
117. Josephs, D.H.; Spicer, J.F.; Karagiannis, P.; Gould, H.J.; Karagiannis, S.N. IgE immunotherapy: a novel 1602 
 concept with promise for the treatment of cancer. mAbs 2014, 6, 54-72, doi: 10.4161/mabs.27029. 1603 
118. Waldmann, T.A.; Iio, A.; Ogawa, M.; McIntyre, O.R.; Strober, W. The metabolism of IgE. Studies in 1604 
 normal individuals and in a patient with IgE myeloma. J. Immunol. 1976, 117, 1139-1144.  1605 
119. Lawrence, M.G.; Woodfolk, J.A.; Schuyler, A.J.; Stillman, L.C.; Chapman, M.D.; Platts-Mills, T.A. 1606 
 Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease. J. 1607 
 Allergy Clin. Immunol. 2017, 139, 422-428, doi: 10.1016/j.jaci.2016.04.056. 1608 
120. Jensen-Jarolim, E.; Bax, H.J.; Bianchini, R.; Capron, M.; Corrigan, C.; Castells, M.; Dombrowicz, D.; 1609 
 Daniels-Wells, T.R.; Fazekas, J.; Fiebiger, E.; Gatault, S.; Gould, H.J.; Janda, J.; Josephs, D.H.; Karagiannis, 1610 
 P.; Levi-Schaffer, F.; Meshcheryakova, A.; Mechtcheriakova, D.; Mekori, Y.; Mungenast, F.; Nigro, E.A.; 1611 
 Penichet, M.L.; Redegeld, F.; Saul, L.; Singer, J.; Spicer, J.F.; Siccardi, A.G.; Spillner, E.; Turner, M.C.; 1612 
 Untersmayr, E.; Vangelista, L.; Karagiannis, S.N. AllergoOncology - the impact of allergy in oncology: 1613 
 EAACI position paper. Allergy 2017, 72, 866-887, doi: 10.1111/all.13119. 1614 
121. Verwaerde, C.; Joseph, M.; Capron, M.; Pierce, R.J.; Damonneville, M.; Velge, F.; Auriault, C.; Capron A. 1615 
 Functional properties of a rat monoclonal IgE antibody specific for Schistosoma mansoni. J. Immunol. 1616 
 1987, 138, 4441-4446. 1617 
122. Vouldoukis, I.; Riveros-Moreno, V.; Dugas, B.; Ouaaz, F.; Bécherel, P.; Debré, P.; Moncada, S.; Mossalayi, 1618 
 M.D. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after 1619 
 ligation of the Fc epsilon RII/CD23 surface antigen. Proc. Natl. Acad. Sci. USA 1995, 92, 7804-7808, doi: 1620 
 10.1073/pnas.92.17.7804. 1621 
123. Vouldoukis, I.; Mazier, D.; Moynet, D.; Thiolat, D.; Malvy, D.; Mossalayi, M.D. IgE mediates killing of 1622 
 intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 1623 
 sensitive pathway. PLoS One 2011, 6, e18289, doi: 10.1371/journal.pone.0018289. 1624 
124. Hagan, P.; Blumenthal, U.J.; Dunn, D.; Simpson, A.J.; Wilkins, H.A. Human IgE, IgG4 and resistance to 1625 
 reinfection with Schistosoma haematobium. Nature 1991, 349, 243-245, doi: 10.1038/349243a0. 1626 
125. Dunne, D.W.; Butterworth, A.E.; Fulford, A.J.; Ouma, J.H.; Sturrock, R.F. Human IgE responses to 1627 
 Schistosoma mansoni and resistance to reinfection. Mem. Inst. Oswaldo Cruz 1992, 87, 99-103, doi: 1628 
 10.1590/S0074-02761992000800014. 1629 
126. Watanabe, N.; Bruschi, F.; Korenaga, M. IgE: a question of protective immunity in Trichinella spiralis 1630 
 infection. Trends Parasitol. 2005, 21, 175-178, doi: 10.1016/j.pt.2005.02.010. 1631 
127. Gounni, A.S.; Lamkhioued, B.; Ochiai, K.; Tanaka, Y.; Delaporte, E.; Capron, A.; Kinet, J.P.; Capron M. 1632 
 High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994, 1633 
 367,183-186, doi: 10.1038/367183a0. 1634 
128. Kamisawa, T.; Zen, Y.; Pillai, S.; Stone J.H. IgG4-related disease. Lancet 2015, 385, 1460-1471, doi: 1635 
 10.1016/S0140-6736(14)60720-0. 1636 
Antibodies 2018, 7, x FOR PEER REVIEW  39 of 44 
 
129. Weindorf, S.C.; Frederiksen, J.K. IgG4-Related Disease: A Reminder for Practicing Pathologists. Arch. 1637 
 Pathol. Lab. Med. 2017, 141, 1476-1483, doi: 10.5858/arpa.2017-0257-RA. 1638 
130.  Wallace, Z.S.; Mattoo, H.; Carruthers, M.; Mahajan, V.S.; Della Torre, E.; Lee, H.; Kulikova, M.; Deshpande, 1639 
 V.; Pillai, S.; Stone, J.H. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 1640 
 concentrations. Ann. Rheum. Dis. 2015, 74, 190-195, doi: 10.1136/annrheumdis-2014-205233. 1641 
131. Crescioli, S.; Correa, I.; Karagiannis, P.; Davies, A.M.; Sutton, B.J.; Nestle, F.O.; Karagiannis, S.N. IgG4 1642 
 Characteristics and Functions in Cancer Immunity. Curr. Allergy Asthma Rep. 2016, 16, 7, doi: 1643 
 10.1007/s11882-015-0580-7. 1644 
132. Liu, Q.; Niu, Z.; Li, Y.; Wang, M.; Pan, B.; Lu, Z.; Liao, Q.; Zhao, Y. Immunoglobulin G4 (IgG4)-positive 1645 
 plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer 1646 
 after curative resection. Cancer Immunol. Immunother. 2016, 65, 931-940, doi: 10.1007/s00262-016-1853-2. 1647 
133. Harada, K.; Shimoda, S.; Kimura, Y.; Sato, Y.; Ikeda, H.; Igarashi, S.; Ren, X.; Sato, H.; Nakanuma, Y. 1648 
 Significance of immunoglobulin G4 (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular 1649 
 mechanism of IgG4 reaction in cancer tissue. Hepatology 2012, 56, 157-164, doi: 10.1002/hep.25627.  1650 
134. Fujimoto, M.; Yoshizawa, A.; Sumiyoshi, S.; Sonobe, M.; Kobayashi, M.; Koyanagi, I.; Aini, W.; 1651 
 Tsuruyama, T.; Date, H.; Haga, H. Stromal plasma cells expressing immunoglobulin G4 subclass in 1652 
 non-small cell lung cancer. Hum. Pathol. 2013, 44, 1569-1576, doi: 10.1016/j.humpath.2013.01.002. 1653 
135. Karagiannis, P.; Gilbert, A.E.; Josephs, D.H.; Ali, N.; Dodev, T.; Saul, L.; Correa, I.; Roberts, L.; 1654 
 Beddowes, E.; Koers, A.; Hobbs, C.; Ferreira, S.; Geh, J.L.; Healy, C.; Harries, M.; Acland, K.M.; Blower, 1655 
 P.J.; Mitchell, T.; Fear, D.J.; Spicer, J.F.; Lacy, K.E.; Nestle, F.O.; Karagiannis, S.N. IgG4 subclass antibodies 1656 
 impair antitumor immunity in melanoma. J. Clin. Invest. 2013, 123, 1457-1474, doi: 10.1172/JCI65579. 1657 
136. Karagiannis, P.; Villanova, F.; Josephs, D.H.; Correa, I.; Van Hemelrijck, M.; Hobbs, C.; Saul, L.; 1658 
 Egbuniwe, I.U.; Tosi, I.; Ilieva, K.M.; Kent, E.; Calonje, E.; Harries, M.; Fentiman, I.; Taylor-Papadimitriou, 1659 
 J.; Burchell, J.; Spicer, J.F.; Lacy, K.E.; Nestle, F.O.; Karagiannis, S.N. Elevated IgG4 in patient circulation is 1660 
 associated with the risk of disease progression in melanoma. Oncoimmunology 2015, 4, e1032492, doi: 1661 
 10.1080/2162402X.2015.1032492. 1662 
137. Karagiannis, P.; Gilbert, A.E.; Nestle, F.O.; Karagiannis, S.N. IgG4 antibodies and cancer-associated 1663 
 inflammation: Insights into a novel mechanism of immune escape. Oncoimmunology 2013, 2, e24889,  doi: 1664 
 10.4161/onci.24889. 1665 
138. Platzer, B.; Elpek, K.G.; Cremasco, V.; Baker, K.; Stout, M.M.; Schultz, C.; Dehlink, E.; Shade, K.T.; 1666 
 Anthony, R.M.; Blumberg, R.S.; Turley, S.J.; Fiebiger, E. IgE/FcεRI-Mediated Antigen Cross-Presentation 1667 
 by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Rep. 2015, 10, 1487-1495, doi: 1668 
 10.1016/j.celrep.2015.02.015. 1669 
139. Platzer, B.; Dehlink, E.; Turley, S.J.; Fiebiger, E. How to connect an IgE-driven response with CTL 1670 
 activity? Cancer Immunol. Immunother. 2012, 61, 1521-1525, doi: 10.1007/s00262-011-1127-y. 1671 
140. Kamta, J.; Chaar, M.; Ande, A.; Altomare, D.A.; Ait-Oudhia, S. Advancing Cancer Therapy with Present 1672 
 and Emerging Immuno-Oncology Approaches. Front. Oncol. 2017, 7, 64, doi: 10.3389/fonc.2017.00064. 1673 
141. Jensen-Jarolim, E.; Turner, M.C.; Karagiannis, S.N. AllergoOncology: IgE- and IgG4-mediated immune 1674 
 mechanisms linking allergy with cancer and their translational implications. J. Allergy Clin. Immunol. 2017, 1675 
 140, 982-984, doi: 10.1016/j.jaci.2017.04.034.  1676 
142. Jensen-Jarolim, E.; Bax, H.J.; Bianchini, R.; Crescioli, S.; Daniels-Wells, T.R.; Dombrowicz, D.; Fiebiger, E.; 1677 
 Gould, H.J.; Irshad, S.; Janda, J.; Josephs, D.H.; Levi-Schaffer, F.; O'Mahony, L.; Pellizzari, G.; Penichet, 1678 
 M.L.; Redegeld, F.; Roth-Walter, F.; Singer, J.; Untersmayr, E.; Vangelista, L.; Karagiannis, S.N. 1679 
 AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy 2018, 73, 328-340, 1680 
 doi: 10.1111/all.13311.  1681 
143. Jensen-Jarolim, E.; Achatz, G.; Turner, M.C.; Karagiannis, S.; Legrand, F.; Capron, M.; Penichet, M.L.; 1682 
 Rodríguez, J.A.; Siccardi, A.G.; Vangelista, L.; Riemer, A.B.; Gould, H. AllergoOncology: the role of 1683 
 IgE-mediated allergy in cancer. Allergy 2008, 63, 1255-1266, doi: 10.1111/j.1398-9995.2008.01768.x. 1684 
144. Karagiannis, S.N.; Josephs, D.H.; Karagiannis, P.; Gilbert, A.E.; Saul, L.; Rudman, S.M.; Dodev, T.; Koers, 1685 
 A.; Blower, P.J.; Corrigan, C.; Beavil, A.J.; Spicer, J.F.; Nestle, F.O.; Gould, H.J. Recombinant IgE antibodies 1686 
 for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol. 1687 
 Immunother. 2012, 61, 1547-1564, doi: 10.1007/s00262-011-1162-8. 1688 
145. Weiner, G.J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 2015, 15, 1689 
 361-370, doi: 10.1038/nrc3930. 1690 
Antibodies 2018, 7, x FOR PEER REVIEW  40 of 44 
 
146. Kunert, R.; Reinhart, D. Advances in recombinant antibody manufacturing. Appl. Microbiol. Biotechnol. 1691 
 2016, 100, 3451-3461, doi: 10.1007/s00253-016-7388-9. 1692 
147. Gould, H.J.; Mackay, G.A.; Karagiannis, S.N.; O'Toole, C.M.; Marsh, P.J.; Daniel, B.E.; Coney, L.R.; 1693 
 Zurawski, V.R. Jr; Joseph, M.; Capron, M.; Gilbert, M.; Murphy, G.F.; Korngold, R. Comparison of IgE and 1694 
 IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. 1695 
 Eur. J. Immunol. 1999, 29, 3527-3537, 1696 
  doi: 10.1002/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5. 1697 
148. Dodev, T.S.; Karagiannis, P.; Gilbert, A.E.; Josephs, D.H.; Bowen, H.; James, L.K.; Bax, H.J.; Beavil, R.; 1698 
 Pang, M.O.; Gould, H.J.; Karagiannis, S.N.; Beavil, A.J. A tool kit for rapid cloning and expression of 1699 
 recombinant antibodies. Sci. Rep. 2014, 4, 5885, doi: 10.1038/srep05885. 1700 
149. Bantleon, F.; Wolf, S.; Seismann, H.; Dam, S.; Lorentzen, A.; Miehe, M.; Jabs, F.; Jakob, T.; Plum, M.; 1701 
 Spillner, E. Human IgE is efficiently produced in glycosylated and biologically active form in lepidopteran 1702 
 cells. Mol. Immunol. 2016, 72, 49-56, doi: 10.1016/j.molimm.2016.02.013. 1703 
150. Montero-Morales, L.; Maresch, D.; Castilho, A.; Turupcu, A.; Ilieva, K.M.; Crescioli, S.; Karagiannis,  S.N.; 1704 
 Lupinek, C.; Oostenbrink, C.; Altmann, F.; Steinkellner, H. Recombinant plant-derived human IgE 1705 
 glycoproteomics. J. Proteomics 2017, 161, 81-87, doi: 10.1016/j.jprot.2017.04.002. 1706 
151. Ilieva, K.M.; Fazekas-Singer, J.; Achkova, D.Y.; Dodev, T.S.; Mele, S.; Crescioli, S.; Bax, H.J.; Cheung, A.; 1707 
 Karagiannis, P.; Correa, I.; Figini, M.; Marlow, R.; Josephs, D.H.; Beavil, A.J.; Maher, J.; Spicer, J.F.; 1708 
 Jensen-Jarolim, E.; Tutt, A.N.; Karagiannis S.N. Functionally Active Fc Mutant Antibodies Recognizing 1709 
 Cancer Antigens Generated Rapidly at High Yields. Front. Immunol. 2017, 8, 1112, doi: 1710 
 10.3389/fimmu.2017.01112. 1711 
152. Fazekas-Singer, J.; Singer, J.; Ilieva, K.M.; Matz, M.; Herrmann, I.; Spillner, E.; Karagiannis, S.N.; 1712 
 Jensen-Jarolim, E. AllergoOncology: Generating a canine anticancer IgE against the epidermal growth 1713 
 factor receptor. J. Allergy Clin. Immunol. 2018, 142, 973-976.e11, doi: 10.1016/j.jaci.2018.04.021. 1714 
153. Crescioli, S.; Chiaruttini, G.; Mele, S.; Ilieva, K.M.; Pellizzari, G.; Spencer, D.I.R.; Gardner, R.A.; Lacy, 1715 
 K.E.; Spicer, J.F.; Tutt, A.N.J.; Wagner, G.K.; Karagiannis, S.N. Engineering and stable production of 1716 
 recombinant IgE for cancer immunotherapy and AllergoOncology. J. Allergy Clin. Immunol. 2018, 141, 1717 
 1519-1523.e9, doi: 10.1016/j.jaci.2017.12.986. 1718 
154. Boscolo, S.; Mion, F.; Licciulli, M.; Macor, P.; De Maso, L.; Brce, M.; Antoniou, M.N.; Marzari, R.; 1719 
 Santoro, C.; Sblattero, D. Simple scale-up of recombinant antibody production using an UCOE containing 1720 
 vector. N. Biotechnol. 2012, 29, 477-484, doi: 10.1016/j.nbt.2011.12.005. 1721 
155. Lu, C.S.; Hung, A.F.; Lin, C.J.; Chen, J.B.; Chen, C.; Shiung, Y.Y.; Tsai, C.Y.; Chang, T.W. Generating 1722 
 allergen-specific human IgEs for immunoassays by employing human ε gene knockin mice. Allergy 2015, 1723 
 70, 384-390, doi: 10.1111/all.12572. 1724 
156. Hecker, J.; Diethers, A.; Schulz, D.; Sabri, A.; Plum, M.; Michel, Y.; Mempel, M.; Ollert, M.; Jakob, T.; 1725 
 Blank, S.; Braren, I.; Spillner, E. An IgE epitope of Bet v 1 and fagales PR10 proteins as defined by a human 1726 
 monoclonal IgE. Allergy 2012, 67, 1530-1537, doi: 10.1111/all.12045. 1727 
157. Correa, I.; Ilieva, K.M.; Crescioli, S.; Lombardi, S.; Figini, M.; Cheung, A.; Spicer, J.F.; Tutt, A.N.J.; Nestle, 1728 
 F.O.; Karagiannis, P.; Lacy, K.E.; Karagiannis, S.N. Evaluation of Antigen-Conjugated Fluorescent Beads to 1729 
 Identify Antigen-Specific B Cells. Front. Immunol. 2018, 9, 493, doi: 10.3389/fimmu.2018.00493. 1730 
158. Nagy, E.; Berczi, I.; Sehon, A.H. Growth inhibition of murine mammary carcinoma by monoclonal IgE 1731 
 antibodies specific for the mammary tumor virus. Cancer Immunol. Immunother. 1991, 34, 63-69, doi: 1732 
 10.1007/BF01741326. 1733 
159. Kershaw, M.H.; Darcy, P.K.; Trapani, J.A.; MacGregor, D.; Smyth, M.J. Tumor-specific IgE-mediated 1734 
 inhibition of human colorectal carcinoma xenograft growth. Oncol. Res. 1998, 10, 133-142. 1735 
160. Daniels, T.R.; Leuchter, R.K.; Quintero, R.; Helguera, G.; Rodríguez, J.A.; Martínez-Maza, O.; Schultes, 1736 
 B.C.; Nicodemus, C.F.; Penichet, M.L. Targeting HER2/neu with a fully human IgE to harness the allergic 1737 
 reaction against cancer cells. Cancer Immunol. Immunother. 2012, 61, 991-1003, doi: 1738 
 10.1007/s00262-011-1150-z. 1739 
161. Teo, P.Z.; Utz, P.J.; Mollick, J.A. Using the allergic immune system to target cancer: activity of IgE 1740 
 antibodies specific for human CD20 and MUC1. Cancer Immunol. Immunother. 2012, 61, 2295-2309, doi: 1741 
 10.1007/s00262-012-1299-0. 1742 
162. Daniels-Wells, T.R.; Helguera, G.; Leuchter, R.K.; Quintero, R.; Kozman, M.; Rodríguez, J.A.; 1743 
 Ortiz-Sánchez, E.; Martínez-Maza, O.; Schultes, B.C.; Nicodemus, C.F.; Penichet, M.L. A novel IgE 1744 
Antibodies 2018, 7, x FOR PEER REVIEW  41 of 44 
 
 antibody targeting the prostate specific antigen as a potential prostate cancer therapy. BMC Cancer 2013, 1745 
 13, 195, doi: 10.1186/1471-2407-13-195.    1746 
163. Karagiannis, P.; Singer, J.; Hunt, J.; Gan, S.K.; Rudman, S.M.; Mechtcheriakova, D.; Knittelfelder, R.; 1747 
 Daniels, T.R.; Hobson, P.S.; Beavil, A.J.; Spicer, J.; Nestle, F.O.; Penichet, M.L.; Gould, H.J.; Jensen-Jarolim, 1748 
 E.; Karagiannis, S.N. Characterisation of an engineered trastuzumab IgE antibody and effector cell 1749 
 mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 2009, 58, 915-930, 1750 
 doi: 10.1007/s00262-008-0607-1. 1751 
164. Spillner, E.; Plum, M.; Blank, S.; Miehe, M.; Singer, J.; Braren I. Recombinant IgE antibody engineering to 1752 
 target EGFR. Cancer Immunol. Immunother. 2012, 61, 1565-1573, doi: 10.1007/s00262-012-1287-4. 1753 
165.  Chung, C.H.; Mirakhur, B.; Chan, E.; Le, Q.T.; Berlin, J.; Morse, M.; Murphy, B.A.; Satinover, S.M.; Hosen, 1754 
 J.; Mauro, D.; Slebos, R.J.; Zhou, Q.; Gold, D.; Hatley, T.; Hicklin, D.J.; Platts-Mills, T.A. 1755 
 Cetuximab-induced  anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008, 1756 
 358, 1109-1117, doi:  10.1056/NEJMoa074943. 1757 
166. Lammerts van Bueren, J.J.; Rispens, T.; Verploegen, S.; van der Palen-Merkus, T.; Stapel, S.; Workman, L.J.; 1758 
 James, H.; van Berkel, P.H.; van de Winkel, J.G.; Platts-Mills, T.A.; Parren, P.W. 1759 
 Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact 1760 
 therapeutic antibody Fc domains. Nat. Biotechnol. 2011, 29, 574-576, doi: 10.1038/nbt.1912. 1761 
167.  Galili, U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. 1762 
 Immunology 2013, 140, 1-11, doi: 10.1111/imm.12110. 1763 
168. Miotti, S.; Canevari, S.; Ménard, S.; Mezzanzanica, D.; Porro, G.; Pupa, S.M.; Regazzoni, M.; Tagliabue, 1764 
 E.; Colnaghi, M. Characterization of human ovarian carcinoma-associated antigens defined by novel 1765 
 monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer 1987, 39, 297-303, doi: 1766 
 10.1002/ijc.2910390306. 1767 
169. Coney, L.R.; Tomassetti, A.; Carayannopoulos, L.; Frasca, V.; Kamen, B.A.; Colnaghi, M.; Zurawski, V.R. 1768 
 Jr. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding 1769 
 protein. Cancer Res. 1991, 51, 6125-6132. 1770 
170. Molthoff, C.F.; Prinssen, H.M.; Kenemans, P.; van Hof, A.C.; den Hollander, W.; Verheijen, R.H. 1771 
 Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian 1772 
 carcinoma patients: a phase I study. Cancer 1997, 80, 2712-2720, 1773 
  doi: 10.1002/(SICI)1097-0142(19971215)80:12+<2712::AID-CNCR50>3.0.CO;2-B. 1774 
171. Buijs, W.C.; Tibben, J.G.; Boerman, O.C.; Molthoff, C.F.; Massuger, L.F.; Koenders, E.B.; Schijf, C.P.; 1775 
 Siegel, J.A.; Corstens, F.H. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian 1776 
 carcinoma patients after intraperitoneal and intravenous administration. Eur. J. Nucl. Med. 1998, 25, 1777 
 1552-1561, doi: 10.1007/s002590050335. 1778 
172. van Zanten-Przybysz, I.; Molthoff, C.; Gebbinck, J.K.; von Mensdorff-Pouilly, S.; Verstraeten, R.; 1779 
 Kenemans, P.; Verheijen, R. Cellular and humoral responses after multiple injections of unconjugated 1780 
 chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J. Cancer Res. Clin. Oncol. 1781 
 2002, 128, 484-492, doi: 10.1007/s00432-002-0348-z. 1782 
173. van Zanten-Przybysz, I.; Molthoff, C.F.; Roos, J.C.; Verheijen, R.H.; van Hof, A.; Buist, M.R.; Prinssen, 1783 
 H.M.; den Hollander, W.; Kenemans, P. Influence of the route of administration on targeting of ovarian 1784 
 cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int. J. Cancer 2001, 92, 106-114, doi: 1785 
 10.1002/1097-0215(200102)9999:9999<::AID-IJC1145>3.0.CO;2-I. 1786 
174. Bell-McGuinn, K.M.; Konner, J.; Pandit-Taskar, N.; Gerst, S.; Nicolaides, N.; Sass, P.; Grasso, L.; Weil, S.; 1787 
 Phillips, M.; Aghajanian, C. A phase I study of MORAb-003, a fully humanized monoclonal antibody 1788 
 against folate receptor alpha, in advanced epithelial ovarian cancer. J. Clin. Oncol. 2007, 25, 5553, doi: 1789 
 10.1200/jco.2007.25.18_suppl.5553. 1790 
175. Konner, J.A.; Bell-McGuinn, K.M.; Sabbatini, P.; Hensley, M.L.; Tew, W.P.; Pandit-Taskar, N.; Vander, 1791 
 Els, N.; Phillips, M.D.; Schweizer, C.; Weil, S.C.; Larson, S.M.; Old, L.J. Farletuzumab, a humanized 1792 
 monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin. 1793 
 Cancer Res, 2010, 16, 5288-5295, doi: 10.1158/1078-0432.CCR-10-0700. 1794 
176. Farrell, C.; Schweizer, C.; Wustner, J.; Weil, S.; Namiki, M.; Nakano, T.; Nakai, K.; Phillips, M.D. 1795 
 Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor 1796 
 alpha, in epithelial ovarian cancer. Cancer Chemother. Pharmacol. 2012, 70, 727-734, doi: 1797 
 10.1007/s00280-012-1959-y. 1798 
Antibodies 2018, 7, x FOR PEER REVIEW  42 of 44 
 
177. Cheung, A.; Opzoomer, J.; Ilieva, K.M.; Gazinska, P.; Hoffmann, R.M.; Mirza, H.; Marlow, R.; 1799 
 Francesch-Domenech, E.; Fittall, M.; Dominguez Rodriguez, D.; Clifford, A.; Badder, L.; Patel, N.; Mele, S.; 1800 
 Pellizzari, G.; Bax, H.J.; Crescioli, S.; Petranyi, G.; Larcombe-Young, D.; Josephs, D.H.; Canevari, S.; Figini, 1801 
 M.; Pinder, S.; Nestle, F.O.; Gillett, C.; Spicer, J.F.; Grigoriadis, A.; Tutt, A.N.J.; Karagiannis S.N. 1802 
 Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast 1803 
 Cancer. Clin. Cancer Res. 2018, 24, 5098-5111, doi: 10.1158/1078-0432.CCR-18-0652. 1804 
178. Tochowicz, A.; Dalziel, S.; Eidam, O.; O'Connell, J.D. 3rd; Griner, S.; Finer-Moore, J.S.; Stroud, R.M. 1805 
 Development and binding mode assessment of 1806 
 N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl] 1807 
 amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that 1808 
 targets tumor cells. J. Med. Chem. 2013, 56, 5446-5455, doi: 10.1021/jm400490e. 1809 
179. Karagiannis, S.N.; Wang, Q.; East, N.; Burke, F.; Riffard, S.; Bracher, M.G.; Thompson, R.G.; Durham, 1810 
 S.R.; Schwartz, L.B.; Balkwill, F.R.; Gould, H.J. Activity of human monocytes in IgE antibody-dependent 1811 
 surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 2003, 33, 1030-1040, doi: 1812 
 10.1002/eji.200323185. 1813 
180. Karagiannis, S.N.; Bracher, M.G.; Beavil, R.L.; Beavil, A.J.; Hunt, J.; McCloskey, N.; Thompson, R.G.; 1814 
 East, N.; Burke, F.; Sutton, B.J.; Dombrowicz, D.; Balkwill, F.R.; Gould, H.J. Role of IgE receptors in IgE 1815 
 antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. 1816 
 Cancer Immunol. Immunother. 2008, 57, 247-263, doi: 10.1007/s00262-007-0371-7. 1817 
181. Rudman, S.M.; Josephs, D.H.; Cambrook, H.; Karagiannis, P.; Gilbert, A.E.; Dodev, T.; Hunt, J.; Koers, 1818 
 A.; Montes, A.; Taams, L.; Canevari, S.; Figini, M.; Blower, P.J.; Beavil, A.J.; Nicodemus, C.F.; Corrigan, C.; 1819 
 Kaye, S.B.; Nestle, F.O.; Gould, H.J.; Spicer, J.F.; Karagiannis, S.N. Harnessing engineered antibodies of the 1820 
 IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a 1821 
 tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin. Exp. Allergy, 2011, 41, 1822 
 1400-1413, doi: 10.1111/j.1365-2222.2011.03770.x. 1823 
182. Karagiannis, S.N.; Bracher, M.G.; Hunt, J.; McCloskey, N.; Beavil, R.L.; Beavil, A.J.; Fear, D.J.; Thompson, 1824 
 R.G.; East, N.; Burke, F.; Moore, R.J.; Dombrowicz, D.D.; Balkwill, F.R.; Gould, H.J. 1825 
 IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of 1826 
 eradication of ovarian cancer cells. J. Immunol. 2007, 179, 2832-2843, doi: 10.4049/jimmunol.179.5.2832. 1827 
183. Kayaba, H.; Dombrowicz, D.; Woerly, G.; Papin, J.P.; Loiseau, S.; Capron, M. Human eosinophils and 1828 
 human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE 1829 
 receptor, but release IL-10 upon receptor activation. J. Immunol. 2001, 167, 995-1003,  doi: 1830 
 10.4049/jimmunol.167.2.995. 1831 
184.  Muraki, M.; Gleich, G.J.; Kita, H. Antigen-specific IgG and IgA, but not IgE, activate the effector functions 1832 
 of eosinophils in the presence of antigen. Int. Arch. Allergy Immunol. 2011, 154, 119-127, doi: 1833 
 10.1159/000320226. 1834 
185. Josephs, D.H.; Bax, H.J.; Dodev, T.; Georgouli, M.; Nakamura, M.; Pellizzari, G.; Saul, L.; Karagiannis, P.; 1835 
 Cheung, A.; Herraiz, C.; Ilieva, K.M.; Correa, I.; Fittall, M.; Crescioli, S.; Gazinska, P.; Woodman, N.; Mele, 1836 
 S.; Chiaruttini, G.; Gilbert, A.E.; Koers, A.; Bracher, M.; Selkirk, C.; Lentfer, H.; Barton, C.; Lever, E.; 1837 
 Muirhead, G.; Tsoka, S.; Canevari, S.; Figini, M.; Montes, A.; Downes, N.; Dombrowicz, D.; Corrigan, C.J.; 1838 
 Beavil, A.J.; Nestle, F.O.; Jones, P.S.; Gould, H.J.; Sanz-Moreno, V.; Blower, P.J.; Spicer, J.F.; Karagiannis, 1839 
 S.N. Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 1840 
 Signaling. Cancer Res. 2017, 77, 1127-1141, doi: 10.1158/0008-5472.CAN-16-1829. 1841 
186. Marquet, R.L.; Westbroek, D.L.; Jeekel, J. Interferon treatment of a transplantable rat colon 1842 
 adenocarcinoma: importance of tumor site. Int. J. Cancer 1984, 33, 689-692, doi: 10.1002/ijc.2910330521. 1843 
187. Bracher, M.; Gould, H.J.; Sutton, B.J.; Dombrowicz, D.; Karagiannis, S.N. Three-colour flow cytometric 1844 
 method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J. Immunol. 1845 
 Methods 2007, 323, 160-171, doi: 10.1016/j.jim.2007.04.009. 1846 
188. Murray, P.J.; Wynn, T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. 1847 
 Immunol. 2011, 11, 723-737, doi: 10.1038/nri3073. 1848 
189. Ruffell, B.; Affara, N.I.; Coussens, L.M. Differential macrophage programming in the tumor 1849 
 microenvironment. Trends Immunol. 2012, 33, 119-126, doi: 10.1016/j.it.2011.12.001. 1850 
190. Mantovani, A.; Biswas, S.K.; Galdiero, M.R.; Sica, A.; Locati, M. Macrophage plasticity and polarization 1851 
 in tissue repair and remodelling. J. Pathol. 2013, 229, 176-185, doi: 10.1002/path.4133. 1852 
Antibodies 2018, 7, x FOR PEER REVIEW  43 of 44 
 
191. Josephs, D.H.; Nakamura, M.; Bax, H.J.; Dodev, T.S.; Muirhead, G.; Saul, L.; Karagiannis, P.; Ilieva, K.M.; 1853 
 Crescioli, S.; Gazinska, P.; Woodman, N.; Lombardelli, C.; Kareemaghay, S.; Selkirk, C.; Lentfer, H.; 1854 
 Barton, C.; Canevari, S.; Figini, M.; Downes, N.; Dombrowicz, D.; Corrigan, C.J.; Nestle, F.O.; Jones, P.S.; 1855 
 Gould, H.J.; Blower, P.J.; Tsoka, S.; Spicer, J.F.; Karagiannis, S.N. An immunologically relevant rodent 1856 
 model demonstrates safety of therapy using a tumour-specific IgE. Allergy 2018, 73, 2328-2341, doi: 1857 
 10.1111/all.13455. 1858 
192. Kraft, S.; Novak, N.; Katoh, N.; Bieber, T.; Rupec, R.A. Aggregation of the high-affinity IgE receptor 1859 
 FcεRI on human monocytes and dendritic cells induces NF-κB activation. J. Invest. Dermatol. 2002, 118, 1860 
 830-837, doi: 10.1046/j.1523-1747.2002.01757.x. 1861 
193. Karagiannis, S.N.; Josephs, D.H.; Bax, H.J.; Spicer, J.F. Therapeutic IgE Antibodies: Harnessing a 1862 
 Macrophage-Mediated Immune Surveillance Mechanism against Cancer. Cancer Res. 2017, 77, 2779-2783, 1863 
 doi: 10.1158/0008-5472.CAN-17-0428. 1864 
194. Ishizaka, T.; Ishizaka, K.; Tomioka, H. Release of histamine and slow reacting substance of anaphylaxis 1865 
 (SRS-A) by IgE-anti-IgE reactions on monkey mast cells. J. Immunol. 1972, 108, 513-520. 1866 
195. Schwartz, L.B. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found. Symp. 2004, 257, 1867 
 65-79. 1868 
196. Dombrowicz, D.; Brini, A.T.; Flamand, V.; Hicks, E.; Snouwaert, J.N.; Kinet, J.P.; Koller, B.H. 1869 
 Anaphylaxis mediated through a humanized high affinity IgE receptor. J. Immunol. 1996, 157, 1645-1651. 1870 
197. Collins, A.M.; Basil, M.; Nguyen, K.; Thelian, D. Rat basophil leukaemia (RBL) cells sensitized with low 1871 
 affinity IgE respond to high valency antigen. Clin. Exp. Allergy 1996, 26, 964-970, doi: 1872 
 10.1111/j.1365-2222.1996.tb00634.x. 1873 
198. Jensen-Jarolim, E.; Singer, J. Why could passive Immunoglobulin E antibody therapy be safe in clinical 1874 
 oncology? Clin. Exp. Allergy 2011, 41, 1337-1340, doi: 10.1111/j.1365-2222.2011.03764.x. 1875 
199. Basal, E.; Eghbali-Fatourechi, G.Z.; Kalli, K.R.; Hartmann, L.C.; Goodman, K.M.; Goode, E.L.; Kamen, 1876 
 B.A.; Low, P.S.; Knutson, K.L. Functional folate receptor alpha is elevated in the blood of ovarian cancer 1877 
 patients. PLoS One 2009, 4, e6292, doi: 10.1371/journal.pone.0006292. 1878 
200. Hoffmann, H.J.; Santos, A.F.; Mayorga, C.; Nopp, A.; Eberlein, B.; Ferrer, M.; Rouzaire, P.; Ebo, D.G.; 1879 
 Sabato, V.; Sanz, M.L.; Pecaric-Petkovic, T.; Patil, S.U.; Hausmann, O.V.; Shreffler, W.G.; Korosec, P.; Knol, 1880 
 E.F. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. 1881 
 Allergy 2015, 70, 1393-1405, doi: 10.1111/all.12698. 1882 
201. Marraccini, P.; Pignatti, P.; D’Alcamo, A.; Salimbeni, R.; Consonni, D. Basophil Activation Test 1883 
 Application in Drug Hypersensitivity Diagnosis: An Empirical Approach. Int. Arch. Allergy Immunol. 1884 
 2018, 177, 160-166, doi: 10.1159/000490116. 1885 
202. Seremet, T.; Haccuria, A.; Lienard, D.; Del Marmol, V.; Neyns, B. Anaphylaxis-like reaction to anti-BRAF 1886 
 inhibitor dabrafenib confirmed by drug provocation test. Melanoma Res. 2019, 29, 95-98, doi: 1887 
 10.1097/CMR.0000000000000529. 1888 
203. Ornelas, C.; Caiado, J.; Campos Melo, A.; Pereira Barbosa, M.; Castells, M.C.; Pereira Dos Santos, M.C. 1889 
 The Contribution of the Basophil Activation Test to the Diagnosis of Hypersensitivity Reactions to 1890 
 Oxaliplatin. Int. Arch. Allergy Immunol. 2018, 177, 274-280, doi: 10.1159/000490313. 1891 
204. De Week, A.L.; Sanz, M.L.; Gamboa, P.M.; Aberer, W.; Bienvenu, J.; Blanca, M.; Demoly, P.; Ebo, D.G.; 1892 
 Mayorga, L.; Monneret, G.; Sainte Laudy, J. Diagnostic tests based on human basophils: more potentials 1893 
 and perspectives than pitfalls. II. Technical issues. J. Investig. Allergol. Clin. Immunol. 2008, 18, 143-155. 1894 
205. Saul, L.; Josephs, D.H.; Cutler, K.; Bradwell, A.; Karagiannis, P.; Selkirk, C.; Gould, H.J.; Jones, P.; Spicer, 1895 
 J.F.; Karagiannis, S.N. Comparative reactivity of human IgE to cynomolgus monkey and human effector 1896 
 cells and effects on IgE effector cell potency. mAbs 2014, 6, 509-522, doi: 10.4161/mabs.27828. 1897 
206. Riemer, A.B.; Untersmayr, E.; Knittelfelder, R.; Duschl, A.; Pehamberger, H.; Zielinski, C.C.; Scheiner, 1898 
 O.; Jensen-Jarolim, E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. 1899 
 Cancer Res. 2007, 67, 3406-3411, doi: 10.1158/0008-5472.CAN-06-3758. 1900 
207. Herrmann, I.; Gotovina, J.; Fazekas-Singer, J.; Fischer, M.B.; Hufnagl, K.; Bianchini, R.; Jensen-Jarolim, E. 1901 
 Canine macrophages can like human macrophages be in vitro activated toward the M2a subtype relevant 1902 
 in allergy. Dev. Comp. Immunol. 2018, 82, 118-127, doi: 10.1016/j.dci.2018.01.005. 1903 
208. Singer, J.; Jensen-Jarolim, E. IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach. 1904 
 J. Carcinog. Mutagen. 2014, 5, 1000176, doi: 10.4172/2157-2518.1000176. 1905 
Antibodies 2018, 7, x FOR PEER REVIEW  44 of 44 
 
209. Carvalho, M.I.; Silva-Carvalho, R.; Pires, I.; Prada, J.; Bianchini, R.; Jensen-Jarolim, E.; Queiroga, F.L. A 1906 
 Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and 1907 
 Dogs. Biomed. Res. Int. 2016, 2016, 4917387, doi: 10.1155/2016/4917387. 1908 
210. Santos, R.B.; Galvão, V.R. Monoclonal Antibodies Hypersensitivity: Prevalence and Management. 1909 
 Immunol. Allergy Clin. North Am. 2017, 37, 695-711, doi: 10.1016/j.iac.2017.07.003.  1910 
211. Cheifetz, A.; Smedley, M.; Martin, S.; Reiter, M.; Leone, G.; Mayer, L.; Plevy, S. The incidence and 1911 
 management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 2003, 98, 1912 
 1315-1324, doi: 10.1111/j.1572-0241.2003.07457.x. 1913 
212. Chen, X.; Churchill, M.J.; Nagar, K.K.; Tailor, Y.H.; Chu, T.; Rush, B.S.; Jiang, Z.; Wang, E.B.; Renz, B.W.; 1914 
 Wang, H.; Fung, M.C.; Worthley, D.L.; Mukherjee, S.; Wang, T.C. IL-17 producing mast cells promote the 1915 
 expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer. Oncotarget 1916 
 2015, 6, 32966-32979, doi: 10.18632/oncotarget.5435. 1917 
213. Welsh, T.J.; Green, R.H.; Richardson, D.; Waller, D.A.; O'Byrne, K.J.; Bradding, P. Macrophage and 1918 
 mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. 1919 
 Clin. Oncol. 2005, 23, 8959-8967, doi: 10.1200/JCO.2005.01.4910. 1920 
214.  Nakae, S.; Suto, H.; Iikura, M.; Kakurai, M.; Sedgwick, J.D.; Tsai, M.; Galli, S.J. Mast cells enhance T cell 1921 
 activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 2006, 176, 1922 
 2238-2248. 1923 
215. Brown, C.E.; Vishwanath, R.P.; Aguilar, B.; Starr, R.; Najbauer, J.; Aboody, K.S.; Jensen, M.C. 1924 
 Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively 1925 
 transferred T cells. J. Immunol. 2007, 179, 3332-3341. 1926 
 1927 
 1928 
 1929 
 © 2018 by the authors. Submitted for possible open access publication under the  1930 
terms and conditions of the Creative Commons Attribution (CC BY) license 1931 
(http://creativecommons.org/licenses/by/4.0/). 1932 
